

REMARKS

Attached as Appendix A is a Version With Markings to Show Changes Made To The Originally Filed Specification (excluding claims) pursuant to 37 CFR §1.125 and Claims pursuant to 37 CFR § 1.21.

In view of all of the foregoing, applicants submit that this case is in condition for allowance and such allowance is earnestly solicited.

Respectfully submitted,

Date: November 14, 2002



Michael L. Goldman
Registration No. 30,727

NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603-1051
Telephone: (585) 263-1304
Facsimile: (585) 263-1600

Appendix A
Version With Markings to Show Changes Made
Page 1 of 72

In reference to the substitute specification, amendments made herein to the originally filed specification, additions appear as underlined text, while deletions appear as bracketed text, as indicated below:

TITLE OF THE INVENTION

*PNEUMOCOCCAL SURFACE PROTEIN C (PspC), EPITOPIC REGIONS
AND STRAIN SELECTION THEREOF, AND USES THEREFOR*

STATEMENT OF GOVERNMENT SUPPORT

[0001] This work was supported in part by National Institute of Health Grants AI21548 and HL58418.

RELATED APPLICATIONS/PATENTS

[This application is based upon and claims priority from U.S. Provisional application Serial No. 60/082,728, filed April 23, 1998.]

[0002] This application is a continuation-in-part ("CIP") of U.S. application Serial No. 08/714,741, filed September 16, 1996, (allowed), which is a CIP of U.S. application Serial No. 08/529,055, filed September 15, 1995. This application is also based upon and claims priority from U.S. Provisional application Serial No. 60/082,728, filed April 23, 1998.

[Reference also is made to: Briles et al., "Strain Selection of Pneumococcal Surface Proteins," U.S. application Serial No. 08/710,749, filed September 20, 1996 (allowed); Briles et al., "Pneumococcal Genes, Portions Thereof, Expression Product Therefrom And Uses of Such Genes, Portions and Products," U.S. applications Serial Nos. 08/714,741, filed September 16, 1996, and 08/529,055, filed September 15, 1995, and PCT applications PCT/US96/14819, filed September 16, 1996 and WO 97/09994, published March 20, 1997; Briles et al. "Oral Administration ...," U.S. application Serial No. 08/482,981, filed June 7, 1995 (allowed), U.S. application Serial No. 08/458,399, filed June 2, 1995 and U.S. application Serial No. 08/657,751, filed May 30, 1996 (allowed); "Mucosal Administration ...," Briles et al., U.S. application Serial No. 08/446,201, filed May 19, 1995 (allowed; filed as a CIP of USSN 08/246,636, filed May 20, 1994 (also allowed)), and Briles et al., U.S. application Serial No. 08/312,949, filed September 30, 1994 (allowed); Briles et al., U.S. application Serial No. 08/319,795, filed May 20, 1994 (allowed); Briles et al., "Epitopic Regions of Pneumococcal Surface Protein A," U.S. application Serial No. 08/456,746, filed

Substitute Specification Correction Page 1(a)

– [Corresponds to Page 1 of Originally Filed Specification]–

Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 2 of 72

June 6, 1995 (now U.S. Patent No. 5,679,768; filed as a cont. USSN 08/048,896, filed April 20, 1993, now abandoned, which was a CIP of USSN 07/835,698, filed February 12, 1992, now abandoned, which was a CIP of USSN 07/656,773, now abandoned); Briles et al., "Structural Gene of Pneumococcal Protein," U.S. application Serial No. 08/467,852, filed June 6, 1995 (now U.S. Patent No. 5,856,170; filed as a cont. of U.S. application Serial No. 08/247,491, filed May 23, 1994), U.S. application Serial No. 08/072,070, filed June 3, 1993 (now U.S. Patent No. 5,476,929) and U.S. Patent Nos. 5,753,463 and 5,728,387 (from U.S. applications Serial Nos. 08/469,434, filed June 6, 1995 and U.S. application Serial No. 214,164, filed March 14, 1994, respectively); Briles et

Substitute Specification Correction Page 1(b)
– [Corresponds to Page 1 of Originally Filed Specification]–
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 3 of 72

al., "Truncated PspA ...," U.S. application Serial No. 08/214,222, filed March 17, 1994 (now U.S. Patent No. 5,804,193); Briles et al. U.S. application Serial No. 08/468,985 (allowed); Briles et al., "Immunoassay Comprising a Truncated Pneumococcal Surface Protein A (PspA)," U.S. Patent No. 5,871,943; U.S. application Serial No. 08/226,844, filed May 29, 1992; 08/093,907, filed July 5, 1994, and 07/889,918, filed July 5, 1994; PCT/US93/05191; and Briles et al., WO 92/1448.]

[0003] Reference also is made to: Briles et al., "Strain Selection of Pneumococcal Surface Proteins," U.S. application Serial No. 08/710,749, filed September 20, 1996, now U.S. Patent No. 5,955,089; PCT applications PCT/US96/14819, filed September 16, 1996 and WO 97/09994, published March 20, 1997; Briles et al. "Oral Administration ...," U.S. application Serial No. 08/482,981, filed June 7, 1995, now U.S. Patent No. 6,232,116, U.S. application Serial No. 08/458,399, filed June 2, 1995, now U.S. Patent No. 6,231,870 and U.S. application Serial No. 08/657,751, filed May 30, 1996, now U.S. Patent No. 6,004,802; "Mucosal Administration ...," Briles et al., U.S. application Serial No. 08/446,201, filed May 19, 1995, now U.S. Patent No. 6,042,832 (filed as a CIP of USSN 08/246,636, filed May 20, 1994, now U.S. Patent No. 5,965,141) and Briles et al., U.S. application Serial No. 08/312,949, filed September 30, 1994, now U.S. Patent No. 6,027,734; Briles et al., "Epitopic Regions of Pneumococcal Surface Protein A," U.S. application Serial No. 08/319,795, filed May 20, 1994 now U.S. Patent No. 5,980,909; Briles et al., "Structural Gene of Pneumococcal Protein", U.S. application Serial No. 08/467,852, filed June 6, 1995, now U.S. Patent No. 5,856,170 (filed as a cont. of U.S. application Serial No. 08/247,491, filed May 23, 1994, now U.S. Patent No. 5,965,400), U.S. application Serial No. 08/072,070, filed June 3, 1993, now U.S. Patent No. 5,476,929, U.S. application Serial No. 08/469,434, filed June 6, 1995, now U.S. Patent No. 5,753,463 and U.S. application Serial No. 08/214,164, filed March 14, 1994, now U.S. Patent No. 5,728,387; Briles et al., "Truncated PspA ...," U.S. application Serial No. 08/214,222, filed March 17, 1994, now U.S. Patent No. 5,804,193 and Briles et al., U.S. application Serial No. 08/468,985, now U.S. Patent No. 5,997,882; Briles et al., "Immunoassay Comprising a Truncated Pneumococcal Surface Protein A (PspA)," U.S. application Serial No. 08/468,718, filed June 6, 1995, now U.S. Patent No. 5,871,943; U.S. application Serial No. 08/226,844, filed May 29, 1992; U.S. applications Serial Nos. 08/093,907, filed July 5, 1994[,] and 07/889,918, filed July 5, 1994, both abandoned; PCT/US93/05191; and Briles et al., WO 92/1448.

Substitute Specification Correction Page 2(a)

- [Corresponds to Page 2 f Originally Filed Specification] -

Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 4 of 72

[0004] Each of these applications and patents, as well as each document or reference cited in each of these applications and patents (including during the prosecution of each issued patent) and PCT and foreign applications or patents corresponding to and/or claiming priority from any of the foregoing applications and patents, is hereby expressly incorporated herein by reference. Documents or references are also cited in the following text, either in a Reference List before the claims, or in the text itself; and, each of these documents or references ("herein-cited documents or references"), as well as each document or reference cited in each of the herein-cited documents or references, is hereby expressly incorporated herein by reference.

FIELD OF THE INVENTION

[0005] The present invention relates to epitopic regions of Pneumococcal Surface Protein C or "PspC", different clades of PspC, isolated and/or purified nucleic acid molecules, such as DNA encoding a fragment or portion of PspC such as an epitopic region of PspC or at least one epitope of PspC, uses for such nucleic acid molecules, e.g., to detect the presence of PspC or of [S.] *Streptococcus pneumoniae* by detecting a nucleic acid molecule therefor in a sample such as by amplification and/or a polymerase chain reaction, vectors or plasmids which contain and/or express such nucleic acid [molecules] molecules, e.g., *in vitro* or *in vivo*, immunological, immunogenic or vaccine compositions comprising at least one PspC and/or a portion thereof (such as at least one epitopic region of at least one PspC and/or at least one polypeptide encoding at least one epitope of at least one PspC), either alone or in further combination with at least one second pneumococcal antigen, such as at least one different PspC and/or a fragment thereof and/or at least one PspA and/or at least one epitopic region of at least one PspA and/or at least polypeptide comprising at least one epitope of PspA.

[0006] PspC or a fragment thereof, and thus a composition comprising PspC or a fragment thereof, can be administered by the same routes, and in approximately the same amounts, as

Appendix A
Version With Markings to Show Changes Made
Page 5 of 72

PspA. Thus, the invention further provides methods for administering PspC or a fragment thereof, as well as uses of PspC or a fragment thereof to formulate such compositions.

[0007] Other aspects of the invention are described in or are obvious from (and within the ambit of the invention) the following disclosure.

BACKGROUND OF THE INVENTION

[0008] [*Streptococcus*] *S. pneumoniae* is an important cause of otitis media, meningitis, bacteremia and pneumonia, and a leading cause of fatal infections in the elderly and persons with underlying medical conditions, such as pulmonary disease, liver disease, alcoholism, sickle cell anemia, cerebrospinal fluid leaks, acquired immune deficiency syndrome (AIDS), and in patients undergoing immunosuppressive therapy. It is also a leading cause of morbidity in young children. Pneumococcal infections cause approximately 40,000 deaths in the U.S. yearly. The most severe pneumococcal infections involve invasive meningitis and bacteremia infections, of which there are 3,000 and 50,000 cases annually, respectively.

[0009] Despite the use of antibiotics and vaccines, the prevalence of pneumococcal infections has declined little over the last twenty-five years; the case-fatality rate for bacteremia is reported to be 15-20% in the general population, 30-40% in the elderly, and 36% in inner-city African Americans. Less severe forms of pneumococcal disease are pneumonia, of which there are 500,000 cases annually in the U.S., and otitis media in children, of which there are an estimated 7,000,000 cases annually in the U.S. caused by pneumococcus. Strains of drug-resistant *S. pneumoniae* are becoming ever more common in the U.S. and worldwide. In some areas, as many as 30% of pneumococcal isolates are resistant to penicillin. The increase in antimicrobial resistant pneumococcus further emphasizes the need for preventing pneumococcal infections.

[0010] Pneumococcus asymptomatically colonizes the upper respiratory tract of normal individuals; disease often results from the spread of organisms from the nasopharynx to other tissues during opportunistic events. The incidence of carriage in humans varies with age and circumstances. Carrier rates in children are typically higher than those of adults. Studies have demonstrated that 38 to 60% of preschool children, 29 to 35% of grammar school children and 9 to 25% of junior high school children are carriers of pneumococcus. Among adults, the rate of carriage drops to 6% for those without children at home, and to 18

Substitute Specification Correction Page 3(a)
- [Corresponds to Page 3 of Originally Filed Specification] -
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 6 of 72

to 29% for those with children at home. It is not surprising that the higher rate of carriage in children than in adults parallels the incidence of pneumococcal disease in these populations.

Substitute Specification Correction Page 3(b)
- [Corresponds to Page 3 of Originally Filed Specification]
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 7 of 72

[0011] An attractive goal for streptococcal vaccination is to reduce carriage in the vaccinated populations and subsequently reduce the incidence of pneumococcal disease. There is speculation that a reduction in pneumococcal carriage rates by vaccination could reduce the incidence of the disease in non-vaccinated individuals as well as in vaccinated individuals. This “herd immunity” induced by vaccination against upper respiratory bacterial pathogens has been observed using the *Haemophilus influenzae* type b conjugate vaccines (Takala, A.K., et al., J. Infect. Dis. 1991; 164: 982-986; Takala, A.K., et al., Pediatr. Infect. Dis. J., 1993; 12: 593-599; Ward, J., et al., Vaccines, S.A. Plotkin and E. A. Mortimer, eds., 1994, pp. 337-386; Murphy, T.V., et al., J. Pediatr., 1993; 122: 517-523; and Mohle-Boetani, J.C., et al., Pediatr. Infect. Dis. J., 1993; 12: 589-593).

[0012] It is generally accepted that immunity to [*Streptococcus*] *S. pneumoniae* can be mediated by specific antibodies against the polysaccharide capsule of the pneumococcus. However, neonates and young children fail to make an adequate immune response against most capsular polysaccharide antigens and can have repeated infections involving the same capsular serotype. One approach to immunizing infants against a number of encapsulated bacteria is to conjugate the capsular polysaccharide antigens to protein to make them immunogenic. This approach has been successful, for example, with [*Haemophilus*] *H. influenzae b* (see U.S. Patent No. 4,496,538 to Gordon and U.S. Patent No. 4,673,574 to Anderson).

[0013] However, there are over ninety known capsular serotypes of *S. pneumoniae*, of which twenty-three account for about 95% of the disease. For a pneumococcal polysaccharide-protein conjugate to be successful, the capsular types responsible for most pneumococcal infections would have to be made adequately immunogenic. This approach may be difficult, because the twenty-three polysaccharides included in the presently-available vaccine are not all adequately immunogenic, even in adults.

[0014] Protection mediated by anti-capsular polysaccharide antibody responses are restricted to the polysaccharide type. Different polysaccharide types differentially facilitate virulence in humans and other species. Pneumococcal vaccines have been developed by combining 23 different capsular polysaccharides that are the prevalent types of human pneumococcal disease. These 23 polysaccharide types have been used in a licensed pneumococcal vaccine since 1983 (D.S. Fedson and D. M. Musher, Vaccines, S.A. Plotkin and J.E.A. Montimer, eds., 1994, pp.

Substitute Specification Correction Page 4
- [Corresponds to Page 4 of Originally Filed Specification] -
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 8 of 72

517-564). The licensed 23-valent polysaccharide vaccine has a reported efficacy of approximately 60% in preventing bacteremia [vaccine type] caused pneumococci in healthy adults.

[0015] However, the efficacy of the vaccine has been controversial, and at times, the justification for the recommended use of the vaccine questioned. It has been speculated that the efficacy of this vaccine is negatively affected by having to combine 23 different antigens. Having a large number of antigens combined in a single formulation may negatively affect the antibody responses to individual types within this mixture because of antigenic competition. The efficacy is also affected by the fact that the 23 serotypes encompass all serological types associated with human infections and carriage.

[0016] An alternative approach to protecting against pneumococcal infection, especially for protecting children, and also the elderly, [from pneumococcal infection,] would be to identify protein antigens that could elicit protective immune responses. Such proteins may serve as a vaccine by themselves, may be used in conjunction with successful polysaccharide-protein conjugates, or as carriers for polysaccharides.

[0017] Pneumococcal Surface Protein A or PspA[,] has been identified as an antigen; and, its DNA and amino acid sequences have been investigated. PspA is useful in eliciting protective immune responses. PspA or fragments thereof can be used in immunological, immunogenic or vaccine compositions; and, such compositions can contain different types of PspAs or fragments from different types of PspAs. Further, such compositions can be administered by injection, or mucosally or orally, or by means of a vector expressing the PspA or fragment thereof.

[0018] Studies on PspA led to the discovery of a PspA-like protein and a *pspA*-like gene, now termed PspC and *pspC*. Indeed, early patent literature termed PspC as “PspA-like”.

[0019] It is believed that heretofore that epitopic regions of PspC have not been disclosed or suggested. It is likewise believed that heretofore different clades of PspC have not been taught or suggested. Further, it is believed that heretofore DNA encoding epitopic regions of PspC have not been disclosed or suggested. Further still, it is believed that heretofore immunological, immunogenic or vaccine compositions comprising at least one PspC and/or portions thereof (such as at least one epitopic region of at least one PspC and/or at least one polypeptide encoding at least one epitope of at least one PspC), either alone or in

Substitute Specification Correction Page 5(a)

- [Corresponds to Page 5 of Originally Filed Specification] –

Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 9 of 72

further combination with at least one second pneumococcal antigen, such as at least one different PspC and/or a fragment thereof

Substitute Specification Correction Page 5(b)
- [Corresponds to Page 5 of Originally Filed Specification] –
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 10 of 72

and/or at least one PspA and/or at least one epitopic region of at least one PspA and/or at least one polypeptide comprising at least one epitope of PspA, have not been taught or suggested.

[0020] Alternative vaccination strategies are desirable as such provide alternative immunological, immunogenic or vaccine compositions, as well as alternative routes to administration or alternative routes to responses. It would be advantageous to provide an immunological composition or vaccination regimen which elicits protection against various diversified pneumococcal strains, without having to combine a large number of possibly competitive antigens within the same formulation. And, it is advantageous to provide additional antigens and epitopes for use in immunological, immunogenic and/or vaccine compositions, e.g., to provide alternative compositions containing or comprising such antigens or epitopes either alone or in combination with different antigens.

[0021] Furthermore it is advantageous to provide a better understanding of the pathogenic mechanisms of pneumococci, as this can lead to the development of improved vaccines, [diagnosis] diagnoses and treatments.

OBJECTS AND SUMMARY OF THE INVENTION

[0022] An object of the invention can include providing one or more of: epitopic regions of PspC, different clades of PspC, isolated and/or purified nucleic acid molecules such as DNA encoding a fragment or portion of PspC such as an epitopic region of PspC or at least one epitope of PspC, uses for such nucleic acid molecules, vectors or plasmids which contain and/or express such nucleic acid [molecules] molecules, e.g., *in vitro* or *in vivo*, immunological, immunogenic or vaccine compositions comprising such a vector or plasmid and/or at least one PspC and/or a portion thereof (such as at least one epitopic region of at least one PspC and/or at least one polypeptide encoding at least one epitope of at least one PspC), either alone or in further combination with at least one second pneumococcal antigen, such as at least one different PspC and/or a fragment thereof and/or at least one PspA and/or at least one epitopic region of at least one PspA and/or at least one polypeptide comprising at least one epitope of PspA and/or at least one vector or plasmid expressing said second pneumococcal antigen (which vector or plasmid could be the same as the aforementioned vector or plasmid [comprising] comprising a nucleic acid molecule encoding PspC or a portion or fragment thereof); and, methods for administering PspC or a fragment thereof, as well as uses of PspC or a fragment thereof to formulate such compositions, *inter alia*.

Substitute Specification Correction Page 6

- [Corresponds to Page 6 of Originally Filed Specification] -

Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 11 of 72

[0023] Accordingly, the invention can provide one or more of: epitopic regions of PspC, different clades of PspC, isolated and/or purified nucleic acid molecules such as DNA encoding a fragment or portion of PspC such as an epitopic region of PspC or at least one epitope of PspC, uses for such nucleic acid molecules, vectors or plasmids which contain and/or express such nucleic acid [molecules] molecules, e.g., *in vitro* or *in vivo*, immunological, immunogenic or vaccine compositions comprising such a vector or plasmid and/or at least one PspC and/or a portion thereof (such as at least one epitopic region of at least one PspC and/or at least one polypeptide encoding at least one epitope of at least one PspC), either alone or in further combination with at least one second pneumococcal antigen, such as at least one different PspC and/or a fragment thereof and/or at least one PspA and/or at least one epitopic region of at least one PspA and/or at least one polypeptide comprising at least one epitope of PspA and/or at least one vector or plasmid expressing said second pneumococcal antigen (which vector or plasmid could be the same as the aforementioned vector or plasmid [comprising] comprising a nucleic acid molecule encoding PspC or a portion or fragment thereof); and, methods for administering PspC or a fragment thereof, as well as uses of PspC or a fragment thereof to formulate such compositions, *inter alia*.

[0024] PspC or a fragment thereof, and thus a composition comprising PspC or a fragment thereof, can be administered by the same routes, and in approximately the same amounts, as PspA. Thus, the invention further provides methods for administering PspC or a fragment thereof, as well as uses of PspC or a fragment thereof to formulate such compositions.

[0025] Still further, the invention provides PspC epitopic regions, e.g., the alpha helical region, or the proline region or the combination of the alpha helical and proline regions, or the entire PspC molecule, or aa 1-590 of PspC clade A, or amino acid(s) ("aa") 1-204 or aa 46-204 or aa 1-295 or aa 46-295 or aa 1-454 or aa 46-454 or aa 204-454 or aa 295-454 or aa 1-590 or aa 46-590 or aa 204-590 or aa 295-590 or aa 454-590 or aa 1-652 or aa 46-652 or aa 204-652 or aa 295-652 or aa 454-652 or aa 590-652 or aa 1-892 or aa 46-892 or aa 204-892 or aa 295-892 or aa 454-892 or 590-892 of PspC clade A. A prototypic clade A PspC is PspC.EF6796. In other clade A PspCs, the epitopic regions may have slightly different amino acid numbers. Thus, the invention comprehends regions of other clade A PspCs which are substantially homologous, or significantly homologous, or highly homologous, or very highly homologous, or identical, or highly conserved, with respect to

Substitute Specification Correction Page 7(a)

- [Corresponds to Page 7 of Originally Filed Specification] -

Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 12 of 72

the foregoing particularly recited epitopic regions. Also, where possible, these regions can extend in either the N-terminal or COOH-terminal direction; e.g., by

Substitute Specification Correction Page 7(b)
- [Corresponds to Page 7 of Originally Filed Specification] –
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 13 of 72

about another 1-25 or 1-50 amino acids in either or both directions. The invention further provides a polypeptide comprising at least one epitopic region or at least one epitope in any one of these various regions.

[0026] Similarly, the invention provides clade B epitopic regions, e.g., the alpha helical region, the proline region, the combination of the alpha helical and proline regions, and the entire molecule, as well as by aa such as aa 1-664, or aa 1-375, or aa 1-445 or aa 1-101, or aa 1-193, or aa 1-262, or aa 1-355, or aa 101-193, or aa 101-262, or aa 101-355, or aa 101-375, or aa 101-455 or aa 193-262, or aa 193-355, or aa 193-375, or aa 193-445 or aa 262-355, or aa 262-375, or aa 262-445 or aa 355-375, or aa 355-445 or aa 375-445 or aa 101-664, or aa 193-664, or aa 262-664, or aa 355-664 or aa 375-664 or aa 1-end of proline subregion A, or aa 1-beginning of proline subregion B, or aa 101-end of proline subregion A, or aa 101-beginning of proline subregion B, or aa 193-end of proline subregion A, or aa 193-beginning of proline subregion B, or aa 262-end of proline subregion A, or aa 262-beginning of proline subregion B, or aa 355-end of proline subregion A, or aa 355-beginning of proline subregion B, or aa 375-end of proline subregion A, or proline subregion A, or aa 375-beginning of proline subregion B, or proline subregion B, or beginning of proline subregion B-aa 664. A prototypic clade B PspC is PspC.D39. In other clade B PspCs, the epitopic regions may have slightly different amino acid numbers. Thus, the invention comprehends regions of other clade B PspCs which are substantially homologous, or significantly homologous, or highly homologous, or very highly homologous, or identical, or highly conserved, with respect to the foregoing particularly recited epitopic regions. Also, where possible, these regions can extend in either the N-terminal or COOH-terminal direction; e.g., by about another 1-25 or 1-50 amino acids in either or both directions. For instance, interesting epitopic regions include: aa 263-482, 1-445 and 255-445. And, the invention further provides a polypeptide comprising at least one epitopic region or at least one epitope in any one of these regions.

[0027] A polypeptide comprising at least one epitope of PspC or PspA can be shorter than natural or full length PspC or PspA, e.g., a truncated PspC or PspA, such as comprising up to about 90% of natural or full length PspC or PspA.

[0028] The invention further provides an isolated nucleic acid molecule, e.g., DNA comprising a sequence encoding any one of these epitopic regions or a polypeptide

Appendix A
Version With Markings to Show Changes Made
Page 14 of 72

comprising at least one of these epitopic regions, or an epitope of PspC; such a nucleic acid molecule is advantageously at

Substitute Specification Correction Page 8(b)
- [Corresponds to Page 8 of Originally Filed Specification] –
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 15 of 72

least about 12 nucleotides in length, for instance, at least about 15, about 18, about 21, about 24 or about 27 nucleotides in length, such as at least about 30, about 33, about 36, about 39 or about 42 nucleotides in length, for example, a nucleic acid molecule of at least about 12 nucleotides in length such as about 12 to about 30, about 12 to about 50 or about 12 to about 60, or about 12 to about 75 or about 12 to about 100 or more nucleotides in length. A nucleic acid molecule comprising a sequence encoding at least one epitope of PspC or PspA can be shorter than natural or full length *pspC* or *pspA*, e.g., a truncated *pspC* or *pspA*, such as comprising up to about 90% of natural or full length *pspC* or *pspA* or encoding up to about 90% of natural or full length PspA or PspC.

[0029] Moreover, in this disclosure, Applicants demonstrate cross-reactivity between PspC and PspA, as well as regions of PspC and PspA and/or of *pspC* and *pspA* which are highly conserved, substantially homologous, highly homologous, and identical. This information allows the skilled artisan to identify nucleic acid molecules which can hybridize, e.g., specifically ("specific hybridization"), to *pspC* or *pspA* or both *pspC* and *pspA*, e.g., under stringent conditions. The term "specific hybridization" will be understood to mean that the nucleic acid probes of the invention are capable of stable, double-stranded hybridization to bacterially-derived DNA or RNA under conditions of high stringency, as the term "high stringency" would be understood by those with skill in the art (see, for example, Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. and Hames and Higgins, eds., 1985, Nucleic Acid Hybridization, IRL Press, Oxford, U.K.). Hybridization will be understood to be accomplished using well-established techniques, including but not limited to Southern blot hybridization, Northern blot hybridization, *in situ* hybridization and, most preferably, Southern hybridization to PCR-amplified DNA fragments. In a preferred alternative, the nucleic acid hybridization probe of the invention may be obtained by use of the polymerase chain reaction (PCR) procedure, using appropriate pairs of PCR oligonucleotide primers as provided herein or from the teachings herein. See U.S. Pat. Nos. 4,683,195 to Mullis et al. and 4,683,202 to Mullis. A probe or primer can be any stretch of at least 8, preferably at least 10, more preferably at least 12, 13, 14, or 15, such as at least 20, e.g., at least 23 or 25, for instance at least 27 or 30 nucleotides in *pspC* which are unique to *pspC*, e.g., not also in *pspA* (when amplification of just *pspC* is desired) or unique to both *pspC* and *pspA* or in both *pspC* and *pspA* (when amplification of both is acceptable or desired) or which are in *pspC* and are least

Substitute Specification Correction Page 9

- [Corresponds to Page 9 of Originally Filed Specification] -

Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 16 of 72

conserved among the *pspC/pspA* genes. As to PCR or hybridization primers or probes and optimal lengths therefor, reference is also made to Kajimura et al., GATA 7(4):71-79 (1990). The invention will thus be understood to provide oligonucleotides, such as[], pairs of oligonucleotides, for use as primers for the *in vitro* amplification of bacterial DNA samples and fragments thereof, or for use in expressing a portion of bacterial DNA, either *in vitro* or *in vivo*. The oligonucleotides preferably specifically hybridize to sequences flanking a nucleic acid to be amplified, wherein the oligonucleotides hybridize to different and opposite strands of the double-stranded DNA target. The oligonucleotides of the invention are preferably derived from the nucleic acid molecules and teachings herein. As used in the practice of this invention, the term “derived from” is intended to encompass the development of such oligonucleotides from the nucleic acid molecules and teachings disclosed herein, from which a multiplicity of alternative and variant oligonucleotides can be prepared.

[0030] And, the invention further comprehends vectors or plasmids containing and/or expressing such a nucleic acid molecule, as well as uses of such nucleic acid molecules, e.g., for expression of PspC or an epitopic region thereof or at least an epitope thereof or a polypeptide comprising at least one epitope thereof either *in vitro* or *in vivo*, or for amplifying or detecting PspC or *S. pneumoniae* in a sample, for instance by a [polymerase chain reaction] PCR.

[0031] With respect to the herein mentioned nucleic acid molecules and polypeptides, e.g., the aforementioned nucleic acid molecules and polypeptides, the invention further comprehends isolated and/or purified nucleic acid molecules and isolated and/or purified polypeptides having at least about 70%, preferably at least about 75% or about 77% identity or homology (“substantially homologous or identical”), advantageously at least about 80% or about 83%, such as at least about 85% or about 87% [homolgy] homology or identity (“significantly homologous or identical”), for instance at least about 90% or about 93% identity or homology (“highly homologous or identical”), more advantageously at least about 95%, e.g., at least about 97%, about 98%, about 99% or even about 100% identity or homology (“very highly homologous or identical” to “identical”; or from about 84-100% identity considered “highly conserved”). The invention also comprehends that these nucleic acid molecules and polypeptides can be used in the same fashion as the herein or aforementioned nucleic acid molecules and polypeptides.

Substitute Specification Correction Page 10(a) –
- [Corresponds to Page 10 of Originally Filed Specification] –
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 17 of 72

[0032] Nucleotide sequence homology can be determined using the “Align” program of Myers and Miller, (“Optimal Alignments in Linear Space”, [CABIOS] [4], 4, 11-17, 1988, incorporated

Substitute Specification Correction Page 10(b)
- [Corresponds to Page 10 of Originally Filed Specification] –
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 18 of 72

herein by reference) and available at NCBI. Alternatively or additionally, the terms “homology” or “identity”, for instance, with respect to a nucleotide or amino acid sequence, can indicate a quantitative measure of homology between two sequences. The percent sequence homology can be calculated as $(N_{ref} - N_{dif}) * 100 / N_{ref}$, wherein N_{dif} is the total number of non-identical residues in the two sequences when aligned and wherein N_{ref} is the number of residues in one of the sequences. Hence, the DNA sequence AGTCAGTC will have a sequence similarity of 75% with the sequence AATCAATC ($N_{ref} = 8$; $N_{dif} = 2$).

[0033] Alternatively or additionally, “homology” or “identity” with respect to sequences can refer to the number of positions with identical nucleotides or amino acids divided by the number of nucleotides or amino acids in the shorter of the two sequences wherein alignment of the two sequences can be determined in accordance with the Wilbur and Lipman algorithm (Wilbur and Lipman, 1983 PNAS USA 80:726, incorporated herein by reference), for instance, using a window size of 20 nucleotides, a word length of 4 nucleotides, and a gap penalty of 4, and computer-assisted analysis and interpretation of the sequence data including alignment can be conveniently performed using commercially available programs (e.g., Intelligenetics™ Suite, Intelligenetics Inc. CA)[.]. When RNA sequences are said to be similar, or have a degree of sequence identity or homology with DNA sequences, thymidine (T) in the DNA sequence is considered equal to uracil (U) in the RNA sequence.

[0034] RNA sequences within the scope of the invention can be derived from DNA sequences, by thymidine (T) in the DNA sequence being considered equal to uracil (U) in RNA sequences.

[0035] Additionally or alternatively, amino acid sequence similarity or identity or homology can be determined using the BlastP program (Altschul *et al.*, Nucl. Acids Res. 25[,] :3389-3402, incorporated herein by reference) and available at NCBI. The following references (each incorporated herein by reference) provide algorithms for comparing the relative identity or homology of amino acid residues of two proteins, and additionally or alternatively with respect to the foregoing, the teachings in these references can be used for determining percent homology or identity: Needleman SB and Wunsch CD, “A general method applicable to the search for similarities in the amino acid sequences of two proteins,” J. Mol. Biol. 48:444-453

Substitute Specification Correction Page 11(a)
- [Corresponds to Page 11 of Originally Filed Specification] –
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 19 of 72

(1970); Smith TF and Waterman MS, "Comparison of Bio-sequences," Advances in Applied Mathematics 2:482-489 (1981); Smith TF, Waterman MS and Sadler JR, "Statistical characterization of nucleic acid sequence functional domains," [Nucleic Acids Res.] Nucl. Acids Res., 11:2205-2220 (1983); Feng DF

Substitute Specification Correction Page 11(b)
- [Corresponds to Page 11 of Originally Filed Specification] -
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 20 of 72

and Dolittle RF, ["Progressive sequence alignment as a prerequisite to correct phylogenetic trees,"] J. [of] Molec. Evol., 25:351-360 (1987); Higgins DG and Sharp PM, ["Fast and sensitive multiple sequence alignment on a microcomputer,"] CABIOS, 5:[]151-153 (1989); Thompson JD, Higgins DG and Gibson TJ, ["Cluster W: improving the sensitivity of progressive multiple sequence alignment through sequence weighing, positions specific gap penalties and weight matrix choice, Nucleic Acids Res.] Nucl. Acids Res., 22:4673-480 (1994); and, Devereux J, Haeblerle P and Smithies O, ["A comprehensive set of sequence analysis program for the VAX, Nucleic Acids Res.] Nucl. Acids Res., 12:[]387-395 (1984).

[0036] A polypeptide comprising at least a fragment or epitope of PspC, e.g., an epitopic region of PspC or PspC, can be a fusion protein; for instance, fused to a protein which enhances immunogenicity, such as a Cholera Toxin, e.g., Cholera Toxin B (CTB).

[0037] Similarly, a polypeptide comprising at least a fragment or epitope of PspC, e.g., an epitopic region of PspC or PspC, can be administered with an adjuvant or a vehicle which enhances immunogenicity, such as CTB.

[0038] Thus, the invention provides an immunological, immunogenic or vaccine composition comprising at least one PspC and/or a portion thereof (such as at least one epitopic region of at least one PspC and/or at least one polypeptide encoding at least one epitope of at least one PspC), either alone or in further combination with at least one second pneumococcal antigen, such as at least one different PspC and/or a fragment thereof and/or at least one PspA and/or at least one epitopic region of at least one PspA and/or at least one polypeptide comprising at least one epitope of PspA. The epitopic region of PspA can be as in applications cited under "Related Applications", *supra*, e.g., aa 1 to 115, 1 to 314, 1 to 260, 192 to 260, 192 to 588, 192 to 299, 1-301, 1-314 or 1-370 of PspA. From the teachings herein and in the applications cited under "Related Applications", the skilled artisan can select an epitope of interest, e.g., of PspC and/or PspA.

[0039] This invention also provides strain selection of PspCs from strains for vaccine compositions, based upon sequence homology and cross-reactivity, akin to that which Applicants have done with PspA. PspC strains can be classified according to sequence homology in the alpha helical and/or proline rich regions, and assigned to a clade, and subsequently, each clade is assigned to a family. Applicants have thus determined that so far there is at least one PspC family with at least two major clades.

Substitute Specification Correction Page 12
- [Corresponds to Page 12 of Originally Filed Specification] -
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 21 of 72

[0040] Inventive compositions, such as immunogenic, immunological or vaccine compositions, can comprise at least one PspC (or [immunogenic] immunogenic fragment thereof or polypeptide comprising at least one PspC epitope or epitopic region or at least one vector or plasmid expressing such PspC or fragment thereof, or at least one PspC epitope or epitopic region), preferably at least two (2), for instance up to ten (10), from strains from each clade (and/or family), alone, or in further combination with at least one PspA (or [immunogenic] immunogenic fragment thereof or polypeptide comprising at least one PspA or at least one epitope or epitopic region of PspA or at least one vector or plasmid expressing such PspA or fragment thereof, or at least one PspA epitope or epitopic region, which vector or plasmid can be the same as the aforementioned vector or plasmid) or preferably at least two (2), for instance up to ten (10), from strains from each PspA clade (and/or family), for a broadly efficacious pneumococcal vaccine with a limited number of strains.

[0041] Immunogenic, immunological or vaccine compositions of the invention can be administered in the same ways as PspA immunogenic, immunological or vaccine compositions, e.g., by injection, mucosally, orally, nasally, and the like, and/or by way of *in vivo* expression thereof by a plasmid or vector, as well as in same or similar regimens (e.g., such as by prime boost) (*see* applications cited under Related Applications, as well as documents cited herein). (Thus, there can be PspA, an epitopic region of PspA, a polypeptide comprising an epitope within an epitopic region of PspA, an immunogenic, immunological or vaccine composition comprising at least one PspA and/or at least one fragment or portion thereof, e.g., an epitopic region thereof or a polypeptide comprising at least one epitope from PspA and/or a vector or plasmid expressing a nucleic acid molecule encoding PspA or a fragment or portion thereof, administration of PspA or such a polypeptide or such a composition by injection, mucosally, nasally, orally, and the like and/or as part of a prime-boost regimen with another antigen which can also be PspA.) The amount of PspC in such compositions can be analogous to the amount of PspA in PspA immunogenic, immunological or vaccine compositions (*see* applications cited under Related Applications). (Accordingly, there can be PspC, an epitopic region of PspC, a polypeptide comprising an epitope within an epitopic region of PspC, an immunogenic, immunological or vaccine composition comprising

Appendix A
Version With Markings to Show Changes Made
Page 22 of 72

at least one PspC and/or at least one fragment or portion thereof, e.g., an epitopic region thereof or a polypeptide comprising at least one epitope from PspC and/or a vector or plasmid expressing a nucleic acid molecule encoding PspC or a fragment or portion thereof, administration of PspC or such a polypeptide or such a

Appendix A
Version With Markings to Show Changes Made
Page 23 of 72

composition by injection, mucosally, nasally, orally, and the like and/or as part of a prime-boost regimen with another antigen which can also be PspC.)

[0042] Such compositions are useful in eliciting an immune response in an animal or a host, such as a protective immune response; or, for generating antibodies, which can be subsequently used in kits, tests or assays for detecting the presence of PspC and/or PspA and PspC and/or *S. pneumoniae*.

[0043] These and other embodiments are disclosed or are obvious from and encompassed by, the following Detailed Description.

BRIEF DESCRIPTION OF FIGURES

[0044] The following Detailed Description, given by way of example, and not intended to limit the invention to specific embodiments described, may be understood in conjunction with the accompanying Figures, incorporated herein by reference, in which:

[0045] Fig. 1 shows a [schmatic] schematic representation of the PspC clade A and clade B and PspA polypeptides in comparison with each other (long arrows represent direct repeats found within the alpha helix; the hypervariable region is indicated by zig-zag lines; and the region of homology of *pspC* with *pspA* found within the alpha helix is indicated by horizontal lines);

[0046] Figs. [2] 2A to 2D show[s] the alignment of PspCs (SEQ ID [NOS:] NOs: 1 to 13) (the amino acid sequences which include[d] the α helical region and the proline-rich region of PspC were aligned using MacVector 6.0; the direct repeats within the α helix, the non-coiled-coil block, and the proline-rich region are indicated with arrows; conserved regions are shaded, and gaps are shown with a dash (-); taxons are named for the strain from which the gene was cloned with the exception of Genbank entrees: SpsA1 (Y10818) from strain ATCC33400 (serotype 1), SpsA2 (AJ002054) from strain ATCC11733 (serotype 2),[,], SpsA47 (AJ002055) from strain NCTC10319 (serotype 47),[,], CbpA (AF019904) from strain LM91 (serotype 2), C3bp (AF067128), and tigr from a serotype 4 clinical isolate (<http://www.tigr.org>); the capsular serotypes of the other strains are as follows: EF6796 (6A), BG8090 (19), L81905 (4), DBL6A (6A), BG9163 (6B), D39 (2) and E134 (23));

Appendix A
Version With Markings to Show Changes Made

Page 24 of 72

[0047] Figs. [3] 3A to 3B show[s] the coiled-coil motif of the alpha-helix of PspC (amino acids that are not in the coiled-coil motif are in the right column; this is the output from the Matcher program) (SEQ ID NO: 14);

[0048] Fig. 4 shows a tree of the PspC proteins from this disclosure and related proteins SpsA and CbpA from Genbank (PspC proteins were truncated after the proline-rich region (Fig. 1) before being aligned using the ClustalW algorithm and the Blosum30 amino acid scoring matrix in MacVector; the tree is an unrooted phylogram generated by the neighbor-joining method using mean character distances in the program PAUP4.0b (Swofford); non-italic numbers on the tree indicate distances along the branch lengths as calculated by PAUP; italic bolded numbers indicate the percentage of time each branch was joined together under bootstrap analysis (1000 replicates performed); Clade A and Clade B are each monophyletic groups separated by greater than 0.1 distance which clustered together 100% of the time; Clade A PspC proteins share a 120 amino acid domain with many PspA proteins (Fig. 2); Clade B proteins lack the 120 AA domain, but all PspC/SpsA/CbpA proteins share the proline-rich domain with PspA proteins; the boxed D39-lineage indicates different sequences for this locus originating from strains that are laboratory descendents of the strain D39; the taxons used were the same as those described for Fig 2);

[0049] Figs. [5] 5A to 5B show[s] PspC and PspA consensus of the choline binding region (SEQ ID NOs: 15-52);

[0050] Fig. 6 shows the reactivity of the PspC antiserum with selected pneumococcal lysates run in a Western immunoblot;

[0051] Fig. 7 shows the level of antibody reactivity to PspC and PspA fragments present in the sera of mice immunized with PspC (each bar represents the mean of the log reciprocal titer and upperbound of the standard error of sera from five mice; the limit of detection of the log reciprocal antibody titer is 1.8);

[0052] Figs. [8] 8A to 8E show[s] amino acid and DNA sequences for SpsA and *spsA* from Genbank (SEQ ID [NOS:] NOs: 53 and 54) (accession CAA05158; AJ002054.1; AJ002054; Hammerschmidt et al. 1997);

Appendix A
Version With Markings to Show Changes Made
Page 25 of 72

[0053] Figs. [9] 9A to 9E show[s] an additional amino acid and DNA sequences for SpsA and *spsA* from Genbank (SEQ ID [NOS:] NOs: 55 and 56) (accession CAA05159; AJ002055; AJ002055.1; Hammerschmidt et al. 1997);

[0054] [Fig. 10] Figs. 10A to 10E show[s] amino acid and DNA sequences for CbpA and *cbpA* from Genbank (SEQ ID NOS: 57 and 58) (accession AAB70838; AF019904; AF019904.1; Rosenow et al. 1997);

[0055] [Fig. 11] Figs. 11A to 11F show[s] amino acid and DNA sequences for PspC and *pspC* from Genbank (SEQ ID [NOS:] NOs: 59 and 60)(from EF6796; accession AAD00184; U72655.1; U72655; Brooks-Walter et al.);

[0056] Fig. 12 shows a tree of PspC proteins from this disclosure from the University of Alabama, analogous to the tree shown in Fig. 4 (PspC proteins sequenced at the University of Alabama; PspC proteins were truncated after the proline-rich region - *see* Fig. 1 - before aligned using the ClustalW algorithm and the Blosom30 amino acid scoring matrix in MacVector; the tree is an unrooted phylogram generated by the neighbor-joining method using mean character distances in the program PAUP4.0b (Swofford); non-italic numbers on the tree indicate distances along the branch lengths as calculated by PAUP; italic bolded numbers indicate the percentage of time each branch was joined together under bootstrap analysis (1000 replicates performed); Clade A and Clade B are monophyletic groups separated by greater than 0.1 distance which clustered together 100% of the time; Clade A PspC proteins share a 120 amino acid domain with many PspA proteins - *see* Fig. 2; taxons are named for the strain from which the gene was cloned, with the capsular serotypes as follows - EF6796 (6A), BG8090 (19), L81905 (4), DBL6A (6a), BG9163 (6B), D39 (2) and E134 (23));

[0057] [Fig. 13] Figs. 13A to 13C show[s] the alignment of PspCs (SEQ ID [NOS:] NOs: 61-67) from this disclosure from the University of Alabama, analogous to the alignment shown in Fig. 2;

[0058] Fig. 14 shows a dendrogram showing the distance of a divergent PspC (from other PspCs), indicating that it likely belongs to a second family (Dendrogram of the PspC/SpsA/Cbpa from Genbank and nearest relative genes from other species; PspC proteins were truncated after the proline-rich region - *see* Fig. 1 - before being aligned using the ClustalW algorithm and the [Blosom30] Blosom 30 amino acid scoring matrix in MacVector; the dendrogram is the guide tree used in alignment by MacVector; small

Substitute Specification Correction Page 16

- [Corresponds to Page 16 of Originally Filed Specification] -

Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 26 of 72

numbers on the tree indicate distances along the branch lengths as calculated during the ClustalW alignment; sequences of two proteins from *Streptococcus agalactiae* *bac* and *rib*, and one from *Enterococcus faecalis* are included for comparison; the PspC.V26 is a highly divergent PspC protein from *S. pneumoniae* strain V26);

[0059] [Fig. 15] Figs. 15A[-] to 15C show[s] the amino acid and DNA sequences (SEQ ID [NOS:] NOs: 68 to 69) of the divergent PspC (PspC from *S. pneumoniae* strain V26);

[0060] Figs. 16[-]A to 21 show the DNA sequences (SEQ ID [NOS.] NOs: 70-75) of PspCs from strains E134 (SEQ ID NO: 70), D39 (SEQ ID NO: 71), BG9163 (SEQ ID NO: 72), BG8090 (SEQ ID NO: 73), L81905 (SEQ ID NO: 74), and DBL6a (SEQ ID NO: 75), respectively.

DETAILED DESCRIPTION

[0061] PspC (see Figs. 1, 2, 3, 4, 5, 11, 12, 13, 14, 15) is one of three designations for a pneumococcal surface protein which is PspA-like, and whose gene is present in approximately 75% of all [*Streptococcus*] *S. pneumoniae*. Applicants have cloned and sequenced the *pspC* gene and have expressed the PspC protein (See, e.g., Figs. 1, 2, 4, 5, 11, 12, 13, and patent applications cited under the heading Related Applications, *supra*, as well as to articles or literature cited herein; see also Figs. 14, 15). Under the designation SpsA (see Figs. 8, 9), PspC has been shown to bind secretory IgA (Hammerschmidt et al. 1997). Under the designation CbpA (see Fig. 10), PspC has been shown to interact with human epithelial and endothelial cells (Rosenow et al. 1997).

[0062] The *pspC* gene is paralogous to the *pspA* gene in *S. pneumoniae* and was thus called *pspC* (Brooks-Walter et al. 1997; see also applications cited in Related Applications, *supra*).

[0063] The present invention provides epitopic regions of PspC, different clades of PspC, DNA encoding epitopic regions of PspC, vectors which express such epitopic regions, immunological, immunogenic or vaccine compositions comprising at least one PspC and/or a portion thereof (such as at least one epitopic region of at least one PspC and/or at least one polypeptide encoding at least one epitope of at least one PspC), either alone or in further combination with at least one second pneumococcal antigen, such as at least one different PspC and/or a fragment thereof and/or at least one PspA and/or at least one epitopic region of at least one PspA and/or at least one polypeptide comprising at least one epitope of PspA.

Substitute Specification Correction Page 17(a) –

[Corresponds to Page 17 of Originally Filed Specification]

Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 27 of 72

[0064] PspC or a fragment thereof, and thus a composition comprising PspC or a fragment thereof, can be administered by the same routes, and in approximately the same amounts, as PspA. Thus, the invention further provides methods for administering PspC or a fragment

Appendix A
Version With Markings to Show Changes Made
Page 28 of 72

thereof or a polypeptide comprising at least one epitope of PspC, as well as uses of PspC or a fragment thereof to formulate such compositions.

[0065] Furthermore, in this disclosure, *pspC* genes from seven different clinical *S. pneumoniae* strains were cloned and sequenced. Examination of the sequences of twelve alleles reveals that this gene exists in diverse forms among [p]Pneumococci and has a mosaic structure in which sequence modules encoding protein domains have contributed to the pattern of variation during gene evolution.

[0066] Two major clades exist: clade A alleles are larger and contain an extra module that is shared by many *pspA* genes; clade B alleles are smaller and lack this *pspA*-like domain. All genes in both clade A and clade B maintain a proline-rich domain and a choline-binding repeat domain that are indistinguishable from similar domains in the *pspA* gene at the nucleotide and protein level.

[0067] Thus, this invention also relates to strain selection of PspCs from strains for vaccine compositions, based upon sequence homology and cross-reactivity, akin to that which Applicants have done with PspA. PspC strains can be classified according to sequence homology in the alpha helical and/or proline rich regions, and assigned to a clade, and subsequently, each clade is assigned to a family. Applicants have thus determined that so far there is one PspC family with at least two major clades.

[0068] There is, however, a single PspC (PspC.V26, from *S. pneumoniae* strain V26, a capsular-type 14 *S. pneumoniae* strain) that appears to be a member of a second family because it seems only distantly related to members of the first major PspC family. Figure 14 provides a dendrogram showing the distance of this divergent PspC from the other PspCs. Fig. 15 provides the amino acid and DNA sequences of the divergent PspC.

[0069] Inventive compositions, such as immunogenic, immunological or vaccine compositions, can comprise at least one PspC (or [immunogenic] immunogenic fragment thereof or polypeptide comprising at least one PspC epitope or epitopic region or at least one vector or plasmid expressing such PspC or fragment thereof, or at least one PspC epitope or epitopic region), preferably at least two (2), for instance up to ten (10), from strains from each clade, alone, or in further combination with at least one PspA (or [immunogenic]

Appendix A
Version With Markings to Show Changes Made

Page 29 of 72

immunogenic fragment thereof or polypeptide comprising at least one PspA or at least one epitope or epitopic region of PspA or at least one vector or plasmid expressing such PspA or fragment thereof, or at least one PspA epitope or epitopic region, which vector or

Substitute Specification Correction Page 18(b)
- [Corresponds to Page 18 of Originally Filed Specification] –
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 30 of 72

plasmid can be the same as the aforementioned vector or plasmid) or preferably at least two (2), for instance up to ten (10), from strains from each PspA clade, for a broadly efficacious pneumococcal vaccine with a limited number of strains.

[0070] Accordingly, in an aspect, the invention provides an immunogenic, immunological or vaccine composition containing an epitope of interest from at least one PspC and/or PspA, and a pharmaceutically acceptable carrier or diluent. An immunological composition elicits an immunological response - local or systemic. The response can, but need not be, protective. An immunogenic composition likewise elicits a local or systemic immunological response which can, but need not be, protective. A vaccine composition elicits a local or systemic protective response. Accordingly, the terms “immunological composition” and “immunogenic composition” include a “vaccine composition” (as the two former terms can be protective compositions).

[0071] The invention therefore also provides a method of inducing an immunological response in a host mammal comprising administering to the host an immunogenic, immunological or vaccine composition. From the disclosure herein and the documents cited herein, including the applications cited under “Related Applications”, the skilled artisan can obtain an epitope of interest of PspC and/or PspA, without undue experimentation.

[0072] Further, the invention demonstrates that more than one serologically complementary PspC molecule can be in an antigenic, immunological or vaccine composition, so as to elicit better response, e.g., protection, for instance, against a variety of strains of [p]Pneumococci; and, the invention provides a system of selecting PspCs for a multivalent composition which includes cross-protection evaluation so as to provide a maximally efficacious composition.

[0073] The determination of the amount of antigen, e.g., PspC or truncated portion thereof or a polypeptide comprising an epitope or epitopic region of PspC, and optional adjuvant in the inventive compositions and the preparation of those compositions can be in accordance with standard techniques well known to those skilled in the pharmaceutical or veterinary arts.

[0074] In particular, the amount of antigen and adjuvant in the inventive compositions and the dosages administered are determined by techniques well known to those skilled in the medical or veterinary arts taking into consideration such factors as the particular antigen, the

Appendix A
Version With Markings to Show Changes Made
Page 31 of 72

adjuvant (if present), the age, sex, weight, species and condition of the particular patient, and the route of administration.

Substitute Specification Correction Page 19(b)
- [Corresponds to Page 19 of Originally Filed Specification] –
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 32 of 72

[0075] For instance, dosages of particular PspC antigens for suitable hosts in which an immunological response is desired, can be readily ascertained by those skilled in the art from this disclosure, as is the amount of any adjuvant typically administered therewith. Thus, the skilled artisan can readily determine the amount of antigen and optional adjuvant in compositions [and] to be administered in methods of the invention. Typically, an adjuvant is commonly used as 0.001 to 50 wt% solution in phosphate buffered saline, and the antigen is present on the order of micrograms to milligrams, such as about 0.0001 to about 5 wt%, preferably about 0.0001 to about 1 wt%, most preferably about 0.0001 to about 0.05 wt% (see, e.g., Examples below or in applications cited herein).

[0076] Typically, however, the antigen is present in an amount on the order of micrograms to milligrams, or, about 0.001 to about 20 wt%, preferably about 0.01 to about 10 wt%, and most preferably about 0.05 to about 5 wt%.

[0077] Of course, for any composition to be administered to an animal or human, including the components thereof, and for any particular method of administration, it is preferred to determine therefor: toxicity, such as by determining the lethal dose (LD) and LD₅₀ in a suitable animal model, e.g., rodent such as mouse; and, the dosage of the composition(s), concentration of components therein and timing of administering the composition(s), which elicit a suitable immunological response, such as by titrations of sera and analysis thereof for antibodies or antigens, e.g., by ELISA and/or RFFIT analysis. Such determinations do not require undue experimentation from the knowledge of the skilled artisan, this disclosure and the documents cited herein. And, the time for sequential administrations can be ascertained without undue experimentation.

[0078] Examples of compositions of the invention include liquid preparations for orifice, e.g., oral, nasal, anal, vaginal, peroral, intragastric, mucosal (e.g., perlingual, alveolar, gingival, olfactory or respiratory mucosa) etc., administration, such as suspensions, syrups or elixirs; and, preparations for parenteral, subcutaneous, intradermal, intramuscular or intravenous administration (e.g., injectable administration), such as sterile suspensions or emulsions. Such compositions may be in admixture with a suitable carrier, diluent, or excipient, such as sterile water, physiological saline, glucose or the like. The compositions can also be lyophilized. The compositions can contain auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, gelling or viscosity enhancing additives, preservatives, flavoring agents, colors,

Substitute Specification Correction Page 20
- [Corresponds to Page 20 of Originally Filed Specification]-
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 33 of 72

and the like, depending upon the route of administration and the preparation desired. Standard texts, such as "REMINGTON'S PHARMACEUTICAL SCIENCE", 17th edition, 1985, incorporated herein by reference, may be consulted to prepare suitable preparations, without undue experimentation.

[0079] Compositions of the invention, are conveniently provided as liquid preparations, e.g., isotonic aqueous solutions, suspensions, emulsions or viscous compositions which may be buffered to a selected pH. If digestive tract absorption is preferred, compositions of the invention can be in the "solid" form of pills, tablets, capsules, caplets and the like, including "solid" preparations [which] that are time-released or [which] that have a liquid filling, e.g., gelatin covered liquid, whereby the gelatin is dissolved in the stomach for delivery to the gut. If nasal or respiratory (mucosal) administration is desired, compositions may be in a form and dispensed by a squeeze spray dispenser, pump dispenser or aerosol dispenser. Aerosols are usually under pressure by means of a hydrocarbon. Pump dispensers can preferably dispense a metered dose or, a dose having a particular particle size.

[0080] Compositions of the invention can contain pharmaceutically acceptable flavors and/or colors for rendering them more appealing, especially if they are administered orally. The viscous compositions may be in the form of gels, lotions, ointments, creams and the like and will typically contain a sufficient amount of a thickening agent so that the viscosity is from about 2500 to 6500 cps, although more viscous compositions, even up to 10,000 cps, may be employed. Viscous compositions have a viscosity preferably of 2500 to 5000 cps, since above that range they become more difficult to administer. However, above that range, the compositions can approach solid or gelatin forms which are then easily administered as a swallowed pill for oral ingestion.

[0081] Liquid preparations are normally easier to prepare than gels, other viscous compositions, and solid compositions. Additionally, liquid compositions are somewhat more convenient to administer, especially by injection or orally, to animals, children, particularly small children, and others who may have difficulty swallowing a pill, tablet, capsule or the like, or in multi-dose situations. Viscous compositions, on the other hand, can be formulated within the appropriate viscosity range to provide longer contact periods with mucosa, such as the lining of the stomach or nasal mucosa.

Appendix A
Version With Markings to Show Changes Made
Page 34 of 72

[0082] Obviously, the choice of suitable carriers and other additives will depend on the exact route of administration and the nature of the particular dosage form, e.g., liquid dosage form (e.g., whether the composition is to be formulated into a solution, a suspension, gel or another liquid form), or solid dosage form (e.g., whether the composition is to be formulated into a pill, tablet, capsule, caplet, time release form or liquid-filled form).

[0083] Solutions, suspensions and gels, normally contain a major amount of water (preferably purified water) in addition to the antigen, lipoprotein and optional adjuvant. Minor amounts of other ingredients, such as pH adjusters (e.g., a base such as NaOH), emulsifiers or dispersing agents, buffering agents, preservatives, wetting agents, jelling agents[,] (e.g., methylcellulose), colors and/or flavors may also be present. The compositions can be isotonic, i.e., it can have the same osmotic pressure as blood and lacrimal fluid.

[0084] The desired isotonicity of the compositions of this invention may be accomplished using sodium chloride, or other pharmaceutically acceptable agents such as dextrose, boric acid, sodium tartrate, propylene glycol or other inorganic or organic solutes. Sodium chloride is preferred particularly for buffers containing sodium ions.

[0085] Viscosity of the compositions may be maintained at the selected level using a pharmaceutically acceptable thickening agent. Methylcellulose is preferred because it is readily and economically available and is easy to work with. Other suitable thickening agents include, for example, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, carbomer, and the like. The preferred concentration of the thickener will depend upon the agent selected. The important point is to use an amount [which] that will achieve the selected viscosity. Viscous compositions are normally prepared from solutions by the addition of such thickening agents.

[0086] A pharmaceutically acceptable preservative can be employed to increase the shelf-life of the compositions. Benzyl alcohol may be suitable, although a variety of preservatives, including, for example, parabens, thimerosal, chlorobutanol, or benzalkonium chloride, may also be employed. A suitable concentration of the preservative will be from 0.02% to 2% based on the total weight although there may be appreciable variation depending upon the agent selected.

Substitute Specification Correction Page 22(a)
- [Corresponds to Page 22 of Originally Filed Specification] -
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 35 of 72

[0087] Those skilled in the art will recognize that the components of the compositions must be selected to be chemically inert with respect to the PspC antigen and optional adjuvant. This will present no problem to those skilled in chemical and pharmaceutical principles, or problems can

Substitute Specification Correction Page 22(b)
- [Corresponds to Page 22 of Originally Filed Specification] –
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 36 of 72

be readily avoided by reference to standard texts or by simple experiments (not involving undue experimentation), from this disclosure and the documents cited herein.

[0088] The immunologically effective compositions of this invention are prepared by mixing the ingredients following generally accepted procedures. For example the selected components may be simply mixed in a blender, or other standard device to produce a concentrated mixture which may then be adjusted to the final concentration and viscosity by the addition of water or thickening agent and possibly a buffer to control pH or an additional solute to control tonicity. Generally the pH may be from about 3 to 7.5. Compositions can be administered in dosages and by techniques well known to those skilled in the medical and veterinary arts taking into consideration such factors as the age, sex, weight, and condition of the particular patient or animal, and the composition form used for administration (e.g., solid vs. liquid). Dosages for humans or other mammals can be determined without undue experimentation by the skilled artisan, from this disclosure, the documents cited herein, and the Examples below (e.g., from the Examples involving mice and from the applications cited herein, e.g., under “Related Applications”, especially since PspC can be administered in a manner and dose analogous to PspA).

[0089] Suitable regimes for initial administration and booster doses or for sequential administrations also are variable, may include an initial administration followed by subsequent administrations; but nonetheless, may be ascertained by the skilled artisan, from this disclosure, the documents cited herein, including applications cited herein, and the Examples below. The compositions can be administered alone, or can be co-administered or sequentially administered with other compositions of the invention or with other prophylactic or therapeutic compositions. Given that PspC is PspA-like, the skilled artisan can readily adjust concentrations of PspA in compositions comprising PspA or a portion thereof to take into account the presence of PspC or a portion thereof in accordance with the herein teachings of compositions comprising at least one PspC or portion thereof and optionally at least one PspA or a portion thereof.

[0090] The PspC antigen (PspC or a portion thereof), as well as a PspA antigen (PspA or a portion thereof) can be expressed recombinantly, e.g., in *E. coli* or in another vector or

Appendix A
Version With Markings to Show Changes Made
Page 37 of 72

plasmid for either *in vivo* expression or *in vitro* expression. The methods for making and/or administering a vector or recombinant or plasmid for expression of PspC or a portion thereof either *in vivo* or *in vitro* can be any desired method, e.g., a method which is by or analogous to

Substitute Specification Correction Page 23(b)
- [Corresponds to Page 23 of Originally Filed Specification] –
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 38 of 72

the methods disclosed in: U.S. Patent Nos. 4,603,112[,] ; 4,769,330[,] ; 5,174,993[,] ; 5,505,941[,] ; 5,338,683[,] ; 5,494,807[,] ; 4,722,848[,] ; WO 94/16716[,] ; WO 96/39491[,] ; Paoletti, ["Applications of pox virus vectors to vaccination: An update,"] [PNAS] Proc. Natl. Acad. Sci. USA 93:11349-11353, [October] 1996[,] ; Moss, ["Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety,"] [PNAS] Proc. Natl. Acad. Sci. USA 93:11341-11348, [October] 1996[,] ; Smith et al., U.S. Patent No. 4,745,051 (recombinant baculovirus)[,] ; Richardson, C.D. (Editor), Methods in Molecular Biology 39, "Baculovirus Expression Protocols" (1995 Humana Press Inc.)[,] ; Smith et al., ["Production of Huma Beta Interferon in Insect with a Baculovirus Expression Vector,"] Molecular and Cellular Biology, [Dec.] 1983, Vol. 3, No. 12, p. 2156-2165; Pennock et al., ["Strong and Regulated Expression of *Escherichia coli* B-Galactosidase in Infect Cells with a Baculovirus vector,"] Molecular and Cellular Biology [Mar.] 1984, Vol. 4, No. 3, p. 399-406; EPA 0 370 573[,] ; U.S. application Serial No. 920,197, filed October 16, 1986[,] ; EP Patent publication No. 265785[,] ; U.S. Patent No. 4,769,331 (recombinant herpesvirus)[,] ; Roizman, ["The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors,"] [PNAS] Proc. Natl. Acad. Sci. USA 93:11307-11312, [October] 1996[,] ; Andreansky et al., ["The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors,"] [PNAS] Proc. Natl. Acad. Sci. USA 93:11313-11318, [October] 1996[,] ; Robertson et al., ["Epstein Barr virus vectors for gene delivery to B lymphocytes,"] [PNAS] Proc. Natl. Acad. Sci. USA 93:11334-11340, [October] 1996 [,] ; Frolov et al., ["Alphavirus based expression vectors: Strategies and applications,"] [PNAS] Proc. Natl. Acad. Sci. USA 93:11371-11377, [October] 1996 [,] ; Kitson et al., J. Virol. 65, 3068-3075, 1991; U.S. Patent Nos. 5,591,439[,] and 5,552,143 (recombinant adenovirus) [,] ; Grunhaus et al., 1992, ["Adenovirus as cloning vectors,"] Seminars in Virology (Vol. 3) p. 237-52, 1993 [,] ; Ballay et al. EMBO Jo

Appendix A
Version With Markings to Show Changes Made
Page 39 of 72

urnal, vol. 4, p. 3861-65 [,] ; Graham, Tibtech 8, 85-87, [April] 1990 [,] ; Prevec et al., J. Gen. Virol. 70, 429-434[,] ; PCT WO91/11525, Felgner et al. (1994), J. Biol. Chem. 269, 2550-2561[,] ; Science, 259:1745-49, 1993 [,] ; [and] McClements et al., ["Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease," PNAS USA 93:11414-11420, October 1996, and U.S. Patents Nos. 5,591,639, 5,589,466, and 5,580,859 relating to DNA expression vectors, *inter alia*. See also, WO 98/335,10; Ju et al., Diabetologia, 41:736-739, 1998 (lentiviral expression system); Sanford et al., U.S. Patent No. 4,945,050 (method for transporting substances into living cells and tissues and apparatus therefor); Fischbach et al., (Intracel), WO 90/01543 (method for the genetic expression of heterologous proteins by cells transfected);

Substitute Specification Correction Page 24(b)
- [Corresponds to Page 24 of Originally Filed Specification] –
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 40 of 72

Robinson et al., seminars in IMMUNOLOGY, vol. 9, pp. 271-283 (1997) (DNA vaccines); Szoka et al., U.S. Patent No. 4,394,448 (method of inserting DNA into living cells); and McCormick et al., U.S. Patent No. 5,677,178 (use of cytopathic viruses for therapy and prophylaxis of neoplasia).

[0091] The expression product generated by vectors or recombinants in this invention optionally can also be isolated and/or purified from infected or transfected cells; for instance, to prepare compositions for administration to patients. However, in certain instances, it may be advantageous to not isolate and/or purify an expression product from a cell; for instance, when the cell or portions thereof enhance the effect of the polypeptide.

[0092] An inventive vector or recombinant expressing PspC or a portion thereof and/or PspA or a portion thereof can be administered in any suitable amount to achieve expression at a suitable dosage level, e.g., a dosage level analogous to the aforementioned dosage levels (wherein the antigen or epitope of interest is directly present). The inventive vector or recombinant can be administered to a patient or infected or transfected into cells in an amount of about at least 10^3 pfu; more preferably about 10^4 pfu to about 10^{10} pfu, e.g., about 10^5 pfu to about 10^9 pfu, for instance about 10^6 pfu to about 10^8 pfu. In plasmid compositions, the dosage should be a sufficient amount of plasmid to elicit a response analogous to compositions wherein PspC or a portion thereof and/or PspA or a portion thereof are directly present; or to have expression analogous to dosages in such compositions; or to have expression analogous to expression obtained *in vivo* by recombinant compositions. For instance, suitable quantities of plasmid DNA in plasmid compositions can be 1 μ g to 100 mg, preferably 0.1 to 10 mg, e.g., 500 micrograms, but lower levels such as 0.1 to 2 mg or preferably 1-10 μ g may be employed. Documents cited herein regarding DNA plasmid vectors may be consulted for the skilled artisan to ascertain other suitable dosages for DNA plasmid vector compositions of the invention, without undue experimentation.

[0093] Returning to our discussion of the examples and results presented herein, a rabbit polyclonal serum to PspC was made by immunization with a recombinant truncated clade B allele. The serum reacted with both PspC and PspA from fifteen (15) pneumococcal isolates indicating that PspC and PspA share extensive cross-reactive epitopes. The cross-reactive antibodies appeared to cause cross-protection in a mouse model system.

Substitute Specification Correction Page 25(a)
- [Corresponds to Page 25 of Originally Filed Specification] -
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 41 of 72

Mice immunized with recombinant clade B PspC were protected against challenge with a strain that expressed PspA

Substitute Specification Correction Page 25(b)
- [Corresponds to Page 25 of Originally Filed Specification] –
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 42 of 72

but not PspC. In this experiment, the PspA-PspC cross-reactive antibodies were directed to the proline-rich domain present in both molecules.

[0094] More in particular, *S. pneumoniae* possess a family of proteins that bind phosphocholine (Brooks-Walter et al. 1997; Garcia et al. 1986; McDaniel et al. 1992) present in the teichoic acid and the lipoteichoic acid of the cell membrane and the cell wall (Tomasz 1967). The choline-binding proteins of [p]Pneumococci and other [g]Gram-positive organisms all contain structurally similar choline-binding domains, which are composed of multiple tandem amino acid repeats (Breise et al. 1985). Autolysin, PspA (pneumococcal surface protein A), and PcpA (pneumococcal choline-binding protein A) of *S. pneumoniae*, toxins A and B of *Clostridium difficile*, glucosyltransferases from *Streptococcus downei* and *Streptococcus mutans*, CspA of *Clostridium acetobilyticum*, and PspA of *Clostridium perfringens* all contain similar regions (Sanchez-Beato et al. 1995; Banas et al. 1990; Barroso et al. 1990; Dove et al. 1990; Garcia et al. 1986; Sanchez-Beato et al. 1998).

[0095] In PspA from *S. pneumoniae*, these choline-binding repeats are responsible for the attachment of PspA to the surface of the pneumococcus (Yother et al. 1994). PspA molecules interfere with complement activation (Briles et al. 1997), slow clearance of [p]Pneumococci from the blood of infected mice (McDaniel et al. 1987), and elicit protection against pneumococcal sepsis and nasal carriage (McDaniel et al. 1991; Wu et al. 1997). A single non-*pspA* locus has been identified which has greater similarity to the choline-binding and proline rich regions of *pspA* than any of the other choline-binding genes (McDaniel et al. 1992). Applicants have designated the molecule PspC because of its strong molecular and serologic similarities to PspA (Brooks-Walter et al. 1997; *see also* applications cited under Related Applications, *supra*, note that in those applications initially PspC was called “PspA-like”, and *pspC* was considered *pspA*-like).

[0096] Other PspA-like proteins and *pspA*-like loci, which could be the same as PspC and *pspC*, have also been characterized and sequenced (SpsA, which reportedly binds secretory IgA, Hammerschmidt et al. 1997; choline-binding protein (for binding a moiety on eukaryotic surfaces), CbpA, Rosenow et. al. 1997; *see, e.g.*, Figs. 8, 9, 10).[.] Immunization with a crude extract of pooled non-PspA choline-binding proteins containing CbpA elicited protection to a lethal challenge of [p]Pneumococci introduced intraperitoneally into mice (Rosenow et al. 1997).

Substitute Specification Correction Page 26
- [Corresponds to Page 26 of Originally Filed Specification] –
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 43 of 72

[0097] In the present studies, Applicants have demonstrated that immunization with purified PspC is able to elicit protection against sepsis, and this protection is apparently mediated by antibodies cross-reactive with PspA. Applicants have also examined the genetic diversity present within this genetic locus, herein called *pspC*, by the examination of 12 sequenced alleles. These include the previously sequenced alleles of *cbpA* and *spsA*, an allele from the genomic sequencing project, and seven newly sequenced *pspC* genes presented here for the first time.

[0098] The sequences of *cbpA* and *spsA* both included sequences of D39 or its derivatives. Rosenow et al. sequenced *cbpA* from LM91 a *pspA*- mutant of D39 (Rosenow et al. 1997); and Hammerschmidt et al. sequenced *spsA* from an encapsulated derivative of R36A (ATCC11733) (Hammerschmidt et al. 1997; *see also* Figs. 8, 9, 10). From a comparison [or] of these two sequences, it was apparent that *spsA* sequence contained a 480 bp deletion within the gene. Because of this discrepancy, Applicants also reported a sequence of *pspC* from a cloned *HindIII-EcoRI* chromosomal fragment of D39 that was determined prior to the *cbpA* and *spsA* sequence (Brooks-Walter et al. 1997; *see also* applications cited under Related Applications, *supra*). This sequence matched exactly that of *cbpA*. Other sequences that were used for sequence alignment comparisons included two *spsA* sequences from capsular serotype 1 and 47 strains (Hammerschmidt et al. 1997), and the *pspC/cbpA/spsA* sequence from the capsular serotype 4 strain sequenced in the TIGR genome project (accessed by the internet at <http://www.tigr.org>).

[0099] The invention shall be further described by way of the following Examples [And] and Results, provided for illustration and not to be considered a limitation of the invention.

EXAMPLES AND RESULTS

Materials and [m]Methods

Bacterial strains, plasmids, and recombinant DNA techniques

[00100] Chromosomal DNA from *S. pneumoniae* EF6796, a serotype 6A clinical isolate (Salser et al. 1993), and D39, a serotype 2 isolate, was isolated using a cesium chloride gradient procedure. The *HindIII-EcoRI* fragment of EF6796 and D39 was cloned in a modified pZero vector (Invitrogen, San Diego, CA) in which the Zeocin-resistance cassette was replaced by a kanamycin cassette, kindly provided by Randall Harris. Recombinant plasmids were electroporated into [*Escherichia*] *E. coli* TOP10F' cells [F' {*lacI*^qTet^R}

Substitute Specification Correction Page 27(a)

- [Corresponds to Page 27 of Originally Filed Specification] -

Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 44 of 72

mcrA_(mrr-hsdRMS-mcrBC) f80lacZ_M15_lacX74 deoR recA1 araD139_(ara-leu)7697
galU galK rpsL endA1

Substitute Specification Correction Page 27(b)
- [Corresponds to Page 27 of Originally Filed Specification] –
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 45 of 72

nupG] (Invitrogen). DNA was purified from agarose using Gene Clean (Bio101, Inc., Vista, CA).

[00101] Chromosomal DNA used for PCR was isolated using a chloroform-isoamyl alcohol procedure. Oligonucleotide primers, ABW13 (5' CGACGAATAGCTGAAGAGG 3') (SEQ ID NO: 76) and SKH2 (5'CATACCGTTTTCTTGTTTCCAGCC 3') (SEQ ID NO: 77), were used to amplify the DNA encoding the alpha-helical region and the proline-rich region of *pspC* in 100 additional *S. pneumoniae* strains. These primers correspond to nucleotides 215-235 and nucleotides 1810-1834, respectively, of the *pspC*/EF6796 gene. PCR products from L81905 (serotype 4), BG9163 (serotype 6B), DBL6A (serotype 6A), BG8090 (serotype 19) and E134 (serotype 23) were cloned into pGem (Promega) or Topo TA vector (Invitrogen) which utilize the A [over hangs] overhangs generated by Taq polymerase.

Sequencing and DNA analysis

[00102] Sequencing of *pspC* was completed using automated DNA sequencing (ABI 377, Applied Biosystems, Inc., Foster City, CA). Sequence analyses were performed using the University of Wisconsin Genetics Computer Group (GCG) programs (Devereux et al. 1984), MacVector 6.5 (Oxford Molecular), Sequencer 3.0 (GeneCodes, Inc.), and DNA Strider programs (Salser et al. 1993). Sequence similarities of *pspC* were determined using the NCBI BLAST.[.] [c]Coil structure predicted by the *pspC* sequence was analyzed using Matcher (Fischetti et al. 1993). The accession number by Genbank/EMBL for the nucleotide sequences of PspC are as follows: EF6796-U72655, DBL6A-AF068645, D39-AF068646, E134 -AF068647, BG8090-AF068648, L81905 - AF068649, BG9163 -AF068650, DBL6A - AF068645, D39 - AF068646, E134 - AF068647, BG8090 - AF068648, L81905 - AF068649, and BG9163 - AF068650; and each of these sequences and GenBank results from the accession numbers are hereby expressly incorporated herein by [refrence] reference (*See also* Figs. 11 and 15-21)[.]. Preliminary sequence data was obtained from The Institute for Genomic Research website at [http://\[www.tigr.org.\] www.tigr.org](http://[www.tigr.org.] www.tigr.org).

Deposit

[00103] *E. coli* containing a cloned PspC gene from *Streptococcus pneumoniae* strain EF6796[,] was deposited on July 24, 2001 with the American Type Culture Collection (ATCC), [12301 Parklawn Drive, Rockville, Maryland, 20852, USA] 10801 University Boulevard, Manassas, VA 20110-2209, under accession number ATCC No. PTA-3526.

Substitute Specification Correction Page 28(a)

- [Corresponds to Page 28 of Originally Filed Specification] –

Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 46 of 72

Example/Result 1: Sequence analysis of *pspC* gene-aspects relating to domain structure and function:

[00104] The protein sequences of *pspC*, *spsA*, and *cbpA* were aligned using MacVector 6.5 (Figures 1, 2, and 13). The predicted amino acid sequences encode proteins ranging in size from 59 to 105 kDa protein. The signal sequences of 37 amino acids are highly conserved (84-100% Identity). The major part of each protein is composed of a large alpha-helical domain (Figures 1,

Appendix A
Version With Markings to Show Changes Made
Page 47 of 72

2, and 13). The N-terminal 100 [-]to 150 amino acids of this alpha-helical domain are hypervariable in both size and sequence and are unique for each strain sequence[d] of unrelated parentage (Figure 2, D39, SpsA2, CbpA, and Cb3P are all from a related lineage; *see also* Fig. 13). In the hypervariable regions of capsular serotype 1 and 4 strains, there is a unique 23 amino acid serine-rich sequence (amino acid positions 112 to 135).

[00105] Downstream of the hypervariable region and central to the alpha-helical domain is the first of two direct repeats. The amino acid repeats (Figures 2, 13) vary in size in individual PspCs from 101 to 205 amino acids and are approximately 79-89% identical at the amino acid level. Smaller-sized amino acid repeats in some strains differ from the larger repeats of other strains only by lack of sequence at the NH₂-terminal end, which accounts for their smaller size. The first repeat in each strain is more like the corresponding first repeat of other strains than it is like the second repeat of the same strain. This pattern suggests that duplication forming this repeat happened in an ancestral gene, prior to the diversification of *pspC* into the numerous divergent alleles seen today. These repeats are highly charged with approximately 45% of their sequence being either lysine or glutamic acid residues. These alpha-helical repeats were present in all alleles that were examined except for the *spsA*//serotype 1 and *spsA*//serotype 2 (Hammerschmidt et al. 1997) (Figures 2, 13).

[00106] Between the amino acid repeats of the alpha-helical domain is a highly conserved 40 amino acid sequence break in the coiled-coil motif which was identified using the Matcher program (Fischetti et al. 1993) (Figures 2, 13 and 3). Matcher examines the characteristic seven residue periodicity of coiled-coil proteins arising largely from the predominance of hydrophobic residues in the first and fourth positions (a and d) and non-hydrophobic residues in the remaining positions (Fischetti et al. 1993). The coiled-coil region of the alpha-helix of PspC/EF6796 has three breaks in the heptad repeat motif (Figure 3). These interruptions of the heptad motif in the 7-residue periodicity were respectively 6, 44 and 5 amino acids in length. Similar breaks at corresponding sequence positions were found in all PspC alleles.

[00107] In some molecules of PspC, the proline-rich region followed the second amino acid repeat (Figures 1, 2, and 13). However, in the three larger PspC molecules, a region very similar to a corresponding region of the *pspA* genetic locus is present. Based on whether this *pspA*-like region was present or absent and on a distance-based cluster analysis, PspC

Substitute Specification Correction Page 29(a)
- [Corresponds to Page 29 of Originally Filed Specification] -
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 48 of 72

molecules were classified into two clades (Figure 4, 12). Clade A molecules contained the *pspA*-like element

Appendix A
Version With Markings to Show Changes Made
Page 49 of 72

and were larger in size. PspC clade B molecules were smaller and lacked this *pspA*-like region. This *pspA*-like region (alpha-helical-2) was present in PspC/BG9163, EF6796 and BG7322 (Figures 1, 2, and 13 and Table 1) as well as in many *pspA* genes.

[00108] Although there is some variation within the proline-rich region of the sequenced PspCs (Figures 1, 2, 13), the region is not distinguishable from the proline-rich region of PspA molecules. Within PspA molecules, two types of proline-rich regions have been identified. One type, which corresponds to about 60% of PspAs, contains a central region of 27 non-proline amino acids, which is highly conserved. The other type of proline-rich region in PspA lacks this conserved non-proline region. In the case of PspC, clade A strains lacked the 27 amino acid non-proline-rich block, whereas the four clade B PspC molecules had this conserved block. When present, the sequence of the 27 amino acid non-proline-rich region is highly conserved between PspC and PspA molecules. No correlation was observed between the expression of this conserved region within PspA and PspC molecules produced by the same strain. The proline-region of SpsA/serotype 1 was different from that of all other PspC molecules. This proline-rich region of this SpsA molecule has a truncated proline-rich region, which contains the 27 amino acid non-proline break but lacks the NH₂ end of the proline-rich region.

[00109] The choline-binding repeat domains of PspC, CbpA and SpsA proteins each contain between 4 and 11 repeats of about 20 amino acids (Figure 5). The repeats found in the center of the choline-binding domain were closest to the consensus sequence, while repeats on the NH₂-terminal and COOH-terminal ends of the block were more distant from the consensus sequence. The arrangement of repeats over the entire choline-binding region in PspC was examined relative to the arrangement of similar repeats in the choline-binding region of five PspC and three PspA genes for which the entire choline-binding domain was sequenced. The following findings all suggested a very close relationship between PspA and PspC in the choline-binding region of the molecule: 1) the NH₂-terminal divergent repeat is identical between the paralogous proteins (PspA and PspC); 2) similarly, the COOH-terminal divergent repeats are very similar between PspC and PspA (see repeats 10 and 11 of PspC consensus and repeats 9 and 10 of PspA consensus – Figure 5), yet these repeats are highly diverged from the rest of the repeat block; 3) the conserved central repeats of the choline-

Substitute Specification Correction Page 30(a)
- [Corresponds to Page 30 of Originally Filed Specification] –
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 50 of 72

binding domain in each case have a single amino acid at position 6 which is frequently asparagine in PspC, but usually tyrosine in PspA proteins[. O] (other than position 6, the consensus repeat for both genes is identical);

Substitute Specification Correction Page 30(b)
- [Corresponds to Page 30 of Originally Filed Specification] –
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 51 of 72

4) [D]ivergence of individual amino acids within the 20 amino acid repeat from the repeat consensus sequence was identical between PspA and PspC (position number 4, 6, 9, 12, 13, 15, 16, and 18); and 5) The repeat blocks are followed by a 17 amino acid partially hydrophobic “tail” that is nearly identical for PspC or PspA except for an additional asparagine present at the end of the PspC proteins that is missing from PspA proteins. Overall, the choline-binding domains of PspA and PspC are so similar that it would not be possible to determine with certainty whether any particular choline-binding domain from these two proteins belongs to PspA or PspC without knowledge of its flanking DNA.

Example/Result 2: Phylogenetic Analysis:

[00110] The *pspA* and *pspC* genes are paralogs of each other because they are both present in the genome of most pneumococci, and because they share high identity in the sequence encoding their COOH-terminal halves (Table 1). An alignment of the 12 PspC/CbpA/SpsA sequences was constructed using the Clustal W algorithm (Figures 2, 13). An unrooted phylogram was produced with PAUP 4.0B with the neighbor-joining method from the mean amino acid distances as calculated over this alignment (Figures 4, 12). The figure as shown incorporates both distance measurements along the branch lengths and bootstrap analysis of 1000 repetitions. Branch length between molecules is proportional to the similarity of the sequences. The tree represents the evolutionary hypothesis that PspC molecules arose in two main clusters representing clades A and B. One clade, A, consisted of the larger PspC molecules, and contained strong identity in alpha-helical region-2 with some *pspA* alleles. The second clade, B, did not contain this region of identity with *pspA* alpha-helical region *pspAs*.

Example/Result 3: Analysis of *pspC* using PCR:

[00111] PCR was used to amplify *pspC* from different strains of *S. pneumoniae* to permit studies of the variability of PspC. Two oligonucleotides which recognized the common sequence regions of *pspC*, but which did not amplify the *pspA* genes, were designed in an effort to permit specific amplification of *pspC* alleles from all pneumococcal strains. Oligonucleotide ABW13 is specific to DNA upstream of the promoter sequence of the *pspC* gene locus. Oligonucleotide SKH2 is specific to the DNA encoding the C-terminal end of the proline-rich region of both the *pspA* and *pspC* gene loci. These oligonucleotides were used to amplify fragments of *pspC* from 100 *S. pneumoniae* strains. Seventy-eight of the 100 strains

Substitute Specification Correction Page 31(a)
- [Corresponds to Page 31 of Originally Filed Specification] –
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 52 of 72

produced PCR-generated fragments, which varied from 1.5 kb to 2.2 kb in size. The remaining 22 strains failed to produce a PCR

Substitute Specification Correction Page 31(b)
- [Corresponds to Page 31 of Originally Filed Specification] –
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 53 of 72

product. Based on the strains of known sequence it was observed that the size of the amplified products correlated with whether they were clade A or clade B. Because of the absence of this *pspA*-conserved region, the clade B *pspC* sequences were smaller than the clade A *pspC*. The amplified product using oligonucleotide ABW13 and SKH2 of clade A molecules was 2.0 kb or greater. The amplified fragment of clade B molecules was approximately 1.6 kb. Approximately 4% of the 75 strains from which a *pspC* gene was amplified were found to be clade A by this criterion and 96% were clade B.

Example/Result 4: Cloning and expression of a recombinant truncated PspC molecules:

[00112] Oligonucleotides were used to amplify a 1.2 kb fragment of L81905, which encodes amino acids 263-482 of the alpha-helix and proline-rich region of PspC. The amplified PCR fragment was cloned into pQE40 (Qiagen, Chatsworth, CA) which allows expression of a fusion product with a polyhistidine tag at the amino-terminal end, followed by [dihydrofolate] dihydrofolate reductase (DHFR), and then by the fragment of PspC/L81905 (263-482). Expression of the fusion protein in [*Escherichia*] E. coli strain BL21(DE3) was induced during growth at room temperature by the addition of 1 mM isopropyl-*b*-d-thiogalactopyranoside (IPTG). The overexpressed fusion protein was purified by affinity chromatography under non-denaturing conditions over a nickel resin according to the manufacturer's protocols. Purified fusion protein was then analyzed by SDS-PAGE and quantitated using a BioRad Protein Assay (Hercules, CA). Two fragments of PspC/D39 (AA 1-445 and AA 255-445), and three fragments of PspA/Rx1 (AA 1-301, AA 1-314 and AA 1-370) were expressed as fusion proteins with 6X His tag in the pET20b expression system (Novagen, Madison, WI). In this case, the overexpressed fusion proteins contain a PelB leader peptide, followed by the PspC or PspA fragments and the His tag at the carboxy-terminus. Expression was induced for pET20b-based constructs with 0.4mM IPTG in the expression strain BL21(DE3), and purified according the manufacturer's protocol.

Example/Result 5: Production of a polyclonal antiserum, SDS-PAGE, and immunoblots:

[00113] The truncated product (AA 263 to 482) of PspC/L81905 was purified by metal affinity chromatography and used to immunize a rabbit. Approximately 4 µg of purified PspC from L81905 was injected two times subcutaneously into a rabbit twice on consecutive

Appendix A
Version With Markings to Show Changes Made
Page 54 of 72

weeks and blood was collected 10 days after the last injection. The primary immunization was with Freund's complete adjuvant and the booster immunization was given in saline. Polyclonal rabbit antiserum was diluted 1:50 and used to analyze pneumococcal lysates on a 7.5% SDS-PAGE gel

Substitute Specification Correction Page 32(b)
- [Corresponds to Page 32 of Originally Filed Specification] –
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 55 of 72

(BioRad, Hercules, CA). Pneumococcal lysates and immunoblots were performed as described by Yother et al. 1994.

Example/Result 6: Cross-reactivity of antisera made to PspC/L81905 with PspA and other PspC molecules:

[00114] A truncated product (AA 263-482) of the PspC/L81905 clade B pspC protein was expressed in *E. coli* using the Qiagen Expression system. It should be noted that PspC/L81905 is clade B and lacks the *pspA*-like region [region] in its alpha-helix. The truncated (AA_263-482) clade B PspC protein was purified by metal affinity chromatography and used to immunize a rabbit to generate a polyclonal antiserum to PspC. Pneumococcal lysates were separated on SDS-polyacrylamide gels and blotted to nitrocellulose. The blots were developed either with Xi126, a monoclonal antibody to PspA, or with the anti-PspC rabbit polyclonal antiserum. The reactivity of the PspC antiserum with selected pneumococcal lysates run in a Western immunoblot is shown in Figure 6.

[00115] The reactivity pattern of the antiserum to PspC was deciphered in part using lysates from *S. pneumoniae* strains JY1119 and JY53. These strains are derivatives of the pneumococcal strains WU2 and D39, respectively, in which the *pspA* genes have been insertionally inactivated (Yother et al 1992). From the Western blot, it is apparent that the polyclonal serum reacts with a 90 kDa band in JY53 even though the *pspA* gene has been inactivated in this strain. This band is assumed to represent PspC. Both JY1119 and its parent, WU2, lack the *pspC* gene altogether (McDaniel et al. 1992). An 85 kDa molecule from WU2 reacts with the anti-PspC antiserum and with the anti-PspA MAb. This band is not present in JY1119, which contains an insertionally inactivated PspA.

[00116] The rabbit antiserum was reactive with proteins in the lysates from all pneumococcal strains tested. The relative molecular weights of the proteins detected also made it apparent that the antiserum was reacting with both PspA and PspC molecules. To distinguish cross-reactivity with the PspA molecule from direct reactivity with the PspC molecule in untested strain lysates a second identical Western blot was developed with a monoclonal antibody specific to PspA molecules (Figure 6, part B). PspC bands could be identified through the comparison of banding patterns in parts A and B of Figure 6. The bands reactive with the anti-PspC rabbit antiserum but not with the anti-PspA MAb were identified as PspC. Bands stained by the rabbit antiserum that co-migrate with those also stained by the MAb were PspA molecules that cross-reacted with

Substitute Specification Correction Page 33
- [Corresponds to Page 33 of Originally Filed Specification] –
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 56 of 72

the antiserum to PspC. Besides failing to react with the [Mab] MAB, it was also noted that PspC bands were of higher molecular weight than the PspA bands. By these criteria the anti-PspC serum cross-reacted with PspA in all strains tested except A66. For A66, a single band was detected. Further testing determined this band to be PspA-derived, rather than PspC-derived. In this case, A66 lacked a *pspC* gene and the PspA of A66 was not reactive with the MAb used, Xi126, even though anti-PspA immune sera does detect PspA in this strain. From the above patterns of reactivity, it was concluded that the PspC polyclonal antiserum is cross-reacting specifically with the PspA molecule.

Example/Result 7: Immunization and challenge studies:

[00117] CBA/N mice were immunized with purified recombinant PspC proteins originating from strain L81905 (AA 263-482), the full alpha-helical region of PspC in strain D39 (AA 1-445), or a truncated portion of the PspC protein in strain D39 (AA 255-445). Each mouse received only one of the above recombinant proteins and groups of 5-6 mice were immunized in each experiment. The mice were immunized subcutaneously with approximately 1 µg of purified protein emulsified in 0.2 ml of complete Freund's adjuvant. Three weeks later they were boosted with 1 µg of purified protein in saline. Three weeks after the boost, the mice were challenged with approximately 700 colony-forming units (CFU) of pneumococcal strain WU2. Control mice were immunized with buffer and complete Freund's adjuvant without PspC.

[00118] Analysis of Immune Sera: Mice were bled retroorbitally 24 hours before challenge. The blood was collected into .5 ml 1% BSA/phosphate buffered saline. Samples were centrifuged for 1 min (2000 rpm) and the supernatant was collected and stored at -20°C until used in direct ELISAs (enzyme-linked immunosorbent assays). Microtiter 96 well plates (Nunc, Weisbaden, Germany) were coated overnight [a] at 4°C with .5 µg of expressed protein which included PspC (AA 1-445) and PspA (UAB55- AA 1-301, UAB15- AA 1-314 and UAB103- AA 1-370). Plates were blocked with 1% bovine serum albumin/phosphate buffered saline (PBS) followed by incubation with immune sera for 3 hours at 37°C. Plates were washed with PBS/DAKO with .15% [t]Tween and incubated with goat anti-mouse immunoglobulin biotin-conjugated antiserum and streptavidin alkaline phosphatase (Southern

Appendix A
Version With Markings to Show Changes Made
Page 57 of 72

Biotechnology Assoc., Birmingham AL). They were developed with p-nitrophenyl phosphate (Sigma, St. Louis, MO). The log reciprocal titer giving 33% maximum binding to the mouse immune sera was determined to evaluate the reactivity.

Substitute Specification Correction Page 34(b)
- [Corresponds to Page 34 of Originally Filed Specification] –
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 58 of 72

[00119] Ability of PspC to elicit protective immunity in mice: Mice were immunized with one of three purified fragments of clade B PspC: L81905 (AA 263-482), D39 (AA 1-445) and D39 (AA 255-445). None of these immunogens contained the *pspA*-like alpha-helical region 2 noted earlier, but all of the immunogens contained the proline-rich region. Mice immunized with PspC and control mice then immunized with adjuvant only were challenged with WU2 or BG7322. WU2 is a capsular serotype 3 strain that produces no detectable PspC and does not contain the structural gene for *pspC* (Figure 6). BG7322 is a capsular serotype 6B strain and contains a clade A PspC molecule. Significant protection against death was seen with both challenge strains in mice immunized with the three different PspC clade B molecules (Table 2). Protective immunity in mice challenged with WU2 must derive from the ability of the PspC immunogen to elicit immunity (presumably mediated by antibodies) in the mice that cross-reacts with the PspA molecule present on surface of strain WU2 because this strain lacks PspC. The ability of PspC to elicit immunity that is directed against PspA was expected from the data herein since PspC had been shown to elicit antibodies cross-reactive with PspA (Figure 6). Protection of the mice challenged with BG7322 was statistically significant even though only 62% of the mice were protected as opposed to 96% when challenged with WU2.

Example/Result 8: Antibody Elicited to Recombinant PspC:

[00120] For this study sera was used from mice immunized with LXS240, which encoded amino acids 255-445 of clade B PspC/D39. This sequence contains the entire proline-rich region of PspC/D39. Direct binding ELISAs were conducted to localize the epitope yielding the cross-reactivity with PspA. Microtiter 96 well plates were coated with fragments of PspC/D39 and PspA/Rx1. Each of the cloned PspA/Rx1 molecules used in these assays expressed the PspA alpha-helical region and differed only in the number of the amino acids it contained in the proline-rich region. UAB55 contained 15 amino acids in the proline-rich region, UAB15 contained 26 amino acids in the proline-rich region, and UAB103 contained the entire proline-rich region. The results from the ELISA are depicted in Figure 7. Mouse antisera only reacted with the PspA/Rx1 molecules containing the entire proline-rich region. The antisera did not react with the PspA molecules UAB55 and UAB15 that contained truncated proline regions. These results strongly suggest that the antibodies elicited by PspC that cross-protect against PspA are probably directed at the proline-rich regions of these molecules. Accordingly, the

Substitute Specification Correction Page 35

- [Corresponds to Page 35 of Originally Filed Specification] -

Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 59 of 72

invention comprehends a method for eliciting anti-PspA antibodies comprising administering PspC or an epitopic region thereof or a polypeptide comprising an epitope of PspC.

Example/Result 9: Modular evolution and chimeric structure of *pspC*:

[00121] PspC is a chimeric protein[,] which has acquired domains from both interspecies and intraspecies genetic exchanges. The protein contains a signal sequence that has 75% nucleotide identity to the *bac* gene from group B streptococci (accession numbers X59771 and X58470) (Hammerschmidt et al. 1997). The *bac* gene encodes the *b* antigen of Group B streptococci, a cell surface receptor that binds the constant region of human IgA. This similar sequence in the signal peptide region suggests that potential interspecies genetic exchange between group B streptococci and *S. pneumoniae* may have formed a chimeric locus including the *bac* regulatory region and a partial *pspA* or a *pspA*-like locus to create an ancestral gene for *pspC*. The origin of the central region specific to the current *pspC* genes is unknown. The direct amino acid repeats of the alpha-helix suggest that this region of PspC has evolved by a domain duplication event. This internal duplication of a portion of the alpha-helix led to gene elongation. The region of the alpha-helix is presumably the functional region of the molecule and reportedly binds SIgA (Hammerschmidt et al. 1997). Further intraspecies variation events are hinted at in the finding that 4% of PspC proteins are of clade A. This clade appears to have derived from a recombination event with PspA (or *visa versa*) providing further evidence of chimeric structure of PspC and possibly PspA molecules.

[00122] Several functions have been attributed to the PspC molecule. In addition to binding secretory IgA and a moiety on the surface of epithelial cells, Hostetter et al. have reported that PspC binds the complement component C3 (Hostetter et al. 1997). Recent studies have shown that PspA inhibits complement activation by inhibiting the formation of the C3 convertase. With the similar structural domains of PspA and PspC, it is conceivable that the virulence properties of the two proteins may complement each other in the host. WU2 is a strain of *S. pneumoniae* that does not contain a structural gene for PspC. When mutants of PspA are produced in WU2 that lacks PspC there is a 10,000-fold decrease in virulence (Briles et al. 1997). When PspA is mutated in D39, a strain that contains both PspA and PspC, there is only a 10-fold decrease in virulence (Briles et al. 1997). From the data herein, PspA and PspC may complement each other in their abilities to block the clearance of

Substitute Specification Correction Page 36(a)
- [Corresponds to Page 36 of Originally Filed Specification] -
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 60 of 72

pneumococci by interfering with the complement pathway (see *also* the preliminary data of Hostetter et al. 1997 and the data of Briles et al. 1997).

Substitute Specification Correction Page 36(b)
- [Corresponds to Page 36 of Originally Filed Specification] –
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 61 of 72

[00123] Rosenow et al. demonstrated that CbpA is expressed more strongly by pneumococci in the nasopharynx than by pneumococci in the blood (Rosenow et al. 1997). Thus, it is feasible that the two molecules may serve the same general function, possibly in different host tissues and in different stages of infection. Furthermore, either molecule may be more critical to virulence in the absence of the other. This hypothesis is further strengthened by data from ongoing studies that show that mutants lacking in both PspC and PspA are significantly decreased in virulence.

[00124] In PspC immunization studies, Applicants challenged mice with a strain expressing both PspC and PspA and a strain expressing PspA but not PspC. By including strains lacking the *pspC* gene Applicants could determine if protection elicited by PspC required the expression of PspC or might act, at least in part, through cross-reactions with PspA. For the study presented, mice were immunized with clade B PspC. This molecule lacks the PspA-PspC homology region near the C-terminal end of the alpha-helical region of PspC. Thus, this immunogen was expected to be one that would give less cross-reaction with PspA than would a clade A PspC. Even so, immunization with PspC/D39 resulted in protection when mice were challenged [with either] either with strain BG7322, [that] which expresses both PspA and PspC, or with strain WU2, which expresses PspA but lacks PspC.

[00125] The protection-eliciting PspC immunogen contained the entire proline-rich region. The alpha-helical regions of PspA/WU2 and PspC/D39 have essentially no homology. However, the proline-rich region of PspC is repetitive and homologous with PspA. It was possible that antibody to this region was responsible for the cross-protection we [have] observed. This hypothesis was supported by the observation that antibody elicited to PspC reacted with PspA fragments that contained the proline-rich region but not with those that lacked the proline-rich region in direct ELISAs. Antibodies elicited by PspC also cross-reacted with PspA on Western blots. The likelihood that the protective cross-reaction of PspC immune sera is mediated through PspA was further strengthened by the sequence data released by TIGR (accessed by the internet at [http://\[www.tigr.org\]](http://www.tigr.org)). Extensive searches of the largely completed genome failed to find other pneumococcal gene sequences with as high a similarity with the PspC sequence domains as the proline-rich region of PspA.

Substitute Specification Correction Page 37(a)
- [Corresponds to Page 37 of Originally Filed Specification] -
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 62 of 72

[00126] Electron microscopy surface labeling studies[,] and epitope mapping studies have localized PspA on the surface of pneumococci with the largely exposed alpha-helical region (Gray, *Pneumococcal infection*, in Bacterial Infection, P.E. Brachman, Ed. 1997, Plenum Pub. Corp.

Substitute Specification Correction Page 37(b)
- [Corresponds to Page 37 of Originally Filed Specification] –
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 63 of 72

NY; McDaniel et al. 1994; McDaniel et al., *Monoclonal antibodies against surface components of Streptococcus pneumoniae*, in *Monoclonal antibodies against bacteria*, A.J.L. Macario and E.C. de Macario, Eds. 1986, Academic Press, Inc. Orlando). Studies by Yother and White have shown that PspA is attached by the C-terminal end to lipoteichoic acids (Yother et al. 1994). No information has been available, however, about whether or not the proline-rich domain is surface exposed. Results from these experiments indicating that antibodies to the proline-rich domain are protective suggest that this domain of PspA is probably accessible on the surface of the pneumococci. This study also provides the first published evidence that antibodies reactive with the proline-rich region of PspA can be protective against pneumococcal infection.

[00127] PspA, PspC/CbpA/SpsA, LytA and PcpA are proteins of *S. pneumoniae* that contain choline-binding domains. The choline-binding domains of PspC/CbpA/SpsA contain between 4 and 11 repeats of about 20 amino acids. The consensus sequences of these repeats are from 90 to 95% identical. The middle region of the choline-binding domain of PspA and PspC is conserved. The first and last two repeats of PspA and PspC differ substantially (by 40 to 65%) from the consensus sequence. Even so, PspA and PspC sequences in these areas generally have the same deviations from the consensus sequence and in most cases are within 95% identical. The choline-binding domains of LytA and PcpA are quite different from that of PspA or PspC (42-62% identity) (Garcia et al. 1986; Sanchez-Beato et al. 1998). Whereas PspA and PspC have most likely evolved by gene duplication, PcpA has probably arisen from horizontal gene transfer. The choline-binding regions of these proteins all support a modular form of evolution of this group of proteins.

[00128] This disclosure provides a comprehensive study of the sequence of *pspC* and shows that PspCs can be divided into two clades based on the sequences in their alpha-helical and proline-rich domains. The disclosure also demonstrates that immunity to the proline-rich domain of PspC can be protective through its recognition of the proline-rich domain of the PspA molecule. The fact that the N-terminal alpha-helical domain of PspC is different from the alpha-helical domain of PspA suggests that PspC and PspA may serve somewhat distinct roles in virulence. However, the fact that the two molecules have a very similar domain

Appendix A
Version With Markings to Show Changes Made
Page 64 of 72

structure and have similarity in much of their sequences raises the possibility that these two molecules may have similar functions. Although there are sequences of a few *pspC* alleles, this is the first report that the PspC family contains two clades and that the PspC molecules [that] contain homology to PspA

Substitute Specification Correction Page 38(b)
- [Corresponds to Page 38 of Originally Filed Specification] –
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 65 of 72

within the cross-protective region of the alpha-helix. The identification of two clades of PspC is pertinent to PspC-containing vaccine, immunological or immunogenic compositions, as well as to methods for identifying PspA, *pspA*, PspC, *pspC*, and/or *S. pneumoniae*.

Moreover, the observation that antibodies to the proline-rich regions of PspA and PspC can be cross-protective facilitates the design of more efficacious vaccines, as well as of alternate vaccines, immunogenic or immunological compositions, e.g., by providing epitopic regions of PspC, epitopes of PspC and nucleic acid molecules encoding the same, and methods for identifying PspA, *pspA*, PspC, *pspC*, and/or *S. pneumoniae*.

[00129] Table 1. Conservation of PspC domains shown as percent amino acid identities.

PspC Domain	PspC vs. PspC	Clade A	Clade B	PspA vs. PspA
		PspC vs. PspA	PspC vs. PspA	
	Orthologous	Paralogous	[p]Paralogous	[o]Orthologous
Upstream through signal	>97%	[N]no alignment possible	no alignment possible	>95%
[p]Peptide				
Whole gene	67.6-99%	14-29%	14-21%	22-79%
Alpha-helical 1	66.9-99.6%	11.8-22.0%	14.8-23.1%	not present
Alpha-helical 2	100%	13.1-88.7%	Not present	14-99%
Proline-rich*	High**	high	High	high
Choline-binding	87%	77%	79.1-99%	77-98%
17 AA tail	100%	88.9%	88.9-94.4%	98-100%
3' downstream	99%	[N]no alignment possible	No alignment possible	N.D.

Percentages calculated using a distance matrix from [Paup] PAUP 3.0.

* All PspA and PspC molecules have a repetitive segment of protein in this region with the motif PEPK or PAPAP. Clade B PspC molecules have a conserved non-repetitive break in the proline-rich region. Distance ranges are uninformative because it is not possible to align these sequences in a meaningful way.

Appendix A
Version With Markings to Show Changes Made
Page 66 of 72

[00130] Table 2. Cross-Protection of CBA/N Mice immunized with Recombinant PspC

Immunogen			immunized ²	[n]Non-immunized ²	P value ¹
PspC fragment	Capsular Serotype of PspC donor	Challenge [s]Strain and Capsular Serotype	# of mice alive/dead ³	# of mice alive/dead ³	
L81905 (AA 263-248)	4	WU2 (3)	13/0	1/12	<.0001
D39 (AA 1-445)	2	WU2 (3)	5/0	0/5	.008
D39 (AA 255-445)	2	WU2 (3)	4/1	0/5	.048
D39 (AA 255-445)	2	BG7322 (6B)	13/8	1/19	.0002

¹ The statistical difference between immunized and non-immunized was calculated using the Fisher exact test.

² Mice were either immunized with PspC with complete Freund's adjuvant or with adjuvant and buffer but no antigen.

³ Mice were challenged 21 days post immunization with 700 CFU of WU2 or 2000 CFU of BG7322 injected i.v. in 0.2 Ringer's injection solution.

* * *

[00131] Having thus described in detail preferred embodiments of the present invention, it is to be understood that the invention defined by the appended claims is not to be limited to particular details set forth in the above description as many apparent variations thereof are possible without departing from the spirit or scope of the present invention.

Appendix A
Version With Markings to Show Changes Made
Page 67 of 72

References

- [00132] 1. S. Hammerschmidt[, S.,] et al., *SpsA, a Novel Pneumococcal Surface Protein with Specific Binding to Secretory Immunoglobulin A and Secretory Component*. Mol. Microbiol., 1997[.], **25**[:], p. 1113-1124.
- [00133] 2. C. Rosenow[, C.,] et al., *Contribution of Novel Choline-Binding Proteins to Adherence, Colonization and Immunogenicity of Streptococcus Pneumoniae*. Mol. Microbiol., 1997[.], **25**[:], p. 819-829.
- [00134] 3. A. Brooks-Walter[, A.,] et al., *The *pspC* Gene Encodes a Second Pneumococcal Surface Protein Homologous to the Gene Encoding the Protection-[Eliciting] Eliciting PspA Protein of Streptococcus Pneumoniae*. ASM [Annual] Annual Meeting (Abstract), 1997.
- [00135] 4. A. Tomasz[, A.,] *Choline in the Cell Wall of a Bacterium: Novel Type of Polymer-Linked Choline in Pneumococcus*. Science, 1967[.], **57**[:], p. 694-697.
- [00136] 5. T. Breise[, T.] and R. Hackenbeck, *Interactions of Pneumococcal Amidase with Lipoteichoic Acid and Choline*. Eur. J. Biochem., 1985[.], **146**[:], p. 417-427.
- [00137] 6. A. Sanchez-Beato[, A.] and J. Garcia, *Molecular Characterization of a Family of Choline-Binding Proteins of Clostridium Acetobutylicum NCIB8052 Accession Number Z50008*[.], 1995.
- [00138] 7. J.A. Banas[, J.A.], R.R.B. Russell, and J.J. Ferretti, *Sequence Analysis of the Gene for the Glucan-Binding Protein of Streptococcus Mutans Ingbritt*[.], 1990.
- [00139] 8. L.A. Barroso[, L.A.,] et al., *Nucleotide Sequence of Clostridium Difficile Toxin B Gene*. Nuc. Acids Res., 1990[.], **18**[:], p. 4004.
- [00140] 9. C.H. Dove[, C.H.,] et al., *Molecular Characterization of the Clostridium Difficile Toxin A Gene*. Infect. Immun., 1990[.], **58**[:], p. 480-488.
- [00141] 10. P. Garcia[, P.,] et al., *Nucleotide Sequence and Expression of the Pneumococcal Autolysin Gene from its Own Promoter in Escherichia Coli*. Gene, 1986[.], **43**[:], p. 265-272.
- [00142] 11. A.R. Sanchez-Beato[, A.R.], R. Lopez, and J.L. Garcia, *Molecular Characterization of PcpA: a Novel Choline-Binding Protein of Streptococcus Pneumoniae*. FEMS Microbiol. Lett., 1998[.], **164**(1) [:], p. 207-214.

Appendix A
Version With Markings to Show Changes Made
Page 68 of 72

- [00143] 12. J. Yother[, J.] and J.M. White, *Novel Surface Attachment Mechanism for the Streptococcus Pneumoniae Protein PspA*. J. Bact., 1994[.], 176[:],p. 2976-2985.
- [00144] 13. D.E. Briles[, D.E.,] et al., *PspA and PspC: Their Potential for Use as Pneumococcal Vaccines*. Microb. Drug Resist., 1997[.], 3[:],p. 401-408.
- [00145] 14. L.S. McDaniel[, L.S.,] et al., *Use of Insertional Inactivation to Facilitate Studies of Biological Properties of Pneumococcal Surface Protein A (PspA)*. J. Exp. Med., 1987[.], 165[:],p. 381-394.
- [00146] 15. L.S. McDaniel[, L. S.,] et al., *PspA, a Surface Protein of Streptococcus Pneumoniae, is Capable of Eliciting Protection Against Pneumococci of More Than One Capsular Type*. Infect. Immun., 1991[.], 59[:],p. 222-228.
- [00147] 16. H.Y. Wu[, H.-Y.,] et al., *Intranasal Immunization of Mice with PspA (Pneumococcal Surface Protein A) Can Prevent Intranasal Carriage and Infection with Streptococcus Pneumoniae*. J. Infect. Dis., 1997[.], 175[:],p. 893-846.
- [00148] 17. L.S. McDaniel[, L.S.,] et al., *Molecular Localization of Variable and Conserved Regions of pspA, and Identification of Additional pspA Homologous Sequences in Streptococcus Pneumoniae*. Microb. Pathog., 1992[.], 13[:],p. 261-269.
- [00149] 18. V.A. Fischetti[, V.A.,] et al., *Identifying Periodic [Occurrences] Occurrences of a Template with Applications to Protein Structure*. Inform. Proc. Letters, 1993[:],p. 11-18.
- [00150] 19. J. Yother[, J.], G.L. Handsome, and D.E. Briles, *Truncated Forms of PspA That Are Secreted from Streptococcus Pneumoniae and Their use in Functional Studies and Cloning of the pspA Gene*. J. Bact., 1992[.], 174[:],p. 610-618.
- [00151] 20. M.K. Hostetter[, M.K.], Q. Cheng, and D.A. Finkel, *C3-Binding Protein (pbcA) in [Streptococcus] Streptococcus Pneumoniae: Accession Number AF067128*. ASM Meeting Miami Beach, Florida [1997,] 1997.
- [00152] 21. B.M. Gray[, B.M.], *[Pneumoccal] Pneumococcal Infection*, in *Bacterial Infection*, P.E. Brachman, Editor.,[] 1997, Plenum Publishing Corporation: New York.
- [00153] 22. L.S. McDaniel[, L.S.,] et al., *Localization of Protection-Eliciting Epitopes on PspA of Streptococcus Pneumoniae Between Amino Acid Residues 192 and 260*. Microb. Pathog., 1994[.], 17[:],p. 323-337.

Substitute Specification Correction Page 42
- [Corresponds to Page 42 of Originally Filed Specification] -
Paragraph Nos. C rrespond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 69 of 72

- [00154] 23. L.S. McDaniel[, L.S.] and D.E. Briles, *Monoclonal Antibodies Against Surface Components of Streptococcus Pneumoniae*, in [Monclonal]Monoclonal Antibodies Against Bacteria, A.J.L. Macario and E.C. de Macario, Editors. [1986,] Academic Press, Inc.: Orlando[.], 1986,[] p. 143.
- [00155] 24. J. Devereux[, J.], P. Haeberli, and O. Smithies, *a Comprehensive Set of Sequence Analysis Programs for the VAX*. Nuc. Acids Res., 1984[.], **12**[:] ,p. 387-395.
- [00156] 25. W. Salser[, W.,] et al., *DNA Sequence Assembly and Editing Products Which Permits Direct Visualization of Raw Data Traces from Automated (Fluorescent) Sequencing Data*. J. NIH Res., 1993, **(5)**[:] ,p. 81-82.
- [00157] 26. R.C. Tart[, RC], L.S. McDaniel, B.A. Ralph, D.E. Briles. *Truncated Streptococcus Pneumoniae PspA Molecules Elicit Cross-Protective Immunity Against Pneumococcal Challenge in Mice*. J. Infect. Dis., 1996, **173**[:] ,380-393[, 1996].
- [00158] 27. D.E. Briles [DE], J.D. King, M.A. Gray, L.S. McDaniel, E. Swiatlo, K.A. Benton. *PspA, a Protection-Eliciting Pneumococcal Protein: Immunogenicity of Isolated Native PspA in Mice*. Vaccine[.], 1996, [**14**[:]] ,858-67. [1996.]
- [00159] 28. M.J. Crain [MJ], J.S. Scott, D.A. Robinson, T.J. Coffey, A. Brooks-Walter, L.S. McDaniel, D.E. Briles. *Evidence for the Simultaneous Expression of Two PspAs by a Clone of Capsular Serotype 6B Streptococcus Pneumoniae*. Microbiol. Patho., 1996, **21**[:] ,265-275. [1996.]
- [00160] 29. M. Yamamoto [M], L.S. McDaniel, K. Kawabata, D.E. Briles, R.J. Jackson, J.R. McGhee, H. Kiyono. *Oral Immunization with PspA Elicits Protective Humoral Immunity Against Streptococcus Pneumoniae Infection*. Infect. Immun., 1997, **56**[:] ,640-644[,1997].
- [00161] 30. H.[ong-]Y.[]Wu, M.[oon] Nahm, Y. Guo, M.[ichael]W. Russell, and D.[avid]E. Briles *Intranasal Immunization of Mice with PspA (Pneumococcal Surface Protein A) Can Prevent Carriage, and Infection with Streptococcus Pneumoniae*. J. Infect. Dis. In Press, 1997.
- [00162] 31. E. Swiatlo [E], A. Brooks-Walter, D.E. Briles, L.S. McDaniel. *Oligonucleotides Identify Conserved and Variable Regions of pspA and pspA-Like Sequences of Streptococcus Pneumoniae*. Gene, 1997, **188(2)**, 279-284[, 1997].
- [00163] 32. L.S. McDaniel [LS], F. Loechel, C. Benedict, T. Greenway, D.E. Briles, R.M. Conry, D.T. Curiel. *Immunization with a Plasmid Expressing Pneumococcal*

Substitute Specification Correction Page 43(a)

- [Corresponds to Page 43 of Originally Filed Specification] -

Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 70 of 72

Surface Protein A (PspA) Can Elicit Protection Against Fatal Infection with Streptococcus Pneumoniae. Gene Therapy, 1997, **4(4)** [:], 375-377[, 1997].

Substitute Specification Correction Page 43(b)
- [Corresponds to Page 43 of Originally Filed Specification] –
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made

Page 71 of 72

- [00164] 33. C. Wortham [C], L. Grinberg, D.C. Kaslow, D.E. Briles, L.S. McDaniel, A. Lees, M. Flora, C.M. Snapper, J.J. Mond. Enhanced Protective Antibody Responses to PspA After Intranasal or Subcutaneous Injection of PspA Genetically Fused to Granulocyte-Macrophage Colony-Stimulating Factor or Interlukin-2. Infect. Immun., 1998, 66[:], 1513-1520. [1998.]
- [00165] 34. A.R. Nayak [AR], S.A. Tinge, R.C. Tart, L.S. McDaniel, D.E. Briles, R. Curtiss III. A Live Recombinant Avirulent Oral Salmonella Vaccine Expressing Pneumococcal Surface Protein a (PspA) Induced Protective Responses Against Streptococcus Pneumoniae. Infect. Immun., 1998, 66[:], 3744-3751. [1998.]
- [00166] 35. L.S. McDaniel [LS], D.O. McDaniel, S.K. Hollingshead, D.E. Briles. Comparison of the PspA Sequence from Streptococcus Pneumoniae EF5668 to the Previously Identified PspA Sequence from Strain Rx1 and the Ability of PspA from EF5668 to Elicit Protection Against Pneumococci of Different Capsular Types. Infect. Immun., 1998, 66[:], 4748-4754 [, 1998].
- [00167] 36. M. Yamamoto [M], D.E. Briles, S. Yamamoto, M. Ohmura, H. Kiyono, J.R. McGhee. A Non-Toxic Adjuvant of Mucosal Immunity to Pneumococcal Surface Protein A. J. Immunol., 1998, 161[:], 4115-4121. [1998.]
- [00168] 37. Abstracts of 89th Annual Meeting of the American Society for Microbiology, p. 125, item D-257, May 1989.
- [00169] 38. Abstracts of 90th Annual Meeting of the American Society for Microbiology, p. 98, item D-106, May 1990.
- [00170] 39. Abstracts of 3rd International ASM Conference on Streptococcal Genetics, p. 11, item 12, June 1990.
- [00171] 40. Talkington et al, Infect. Immun., 1991, 59[:], 1285-1289[, 1991].
- [00172] 41. Yother et al., J. Bacteriol., 1992, 174[:], 601-609[, 1992].
- [00173] 42. McDaniel et al., J. Exp. Med., 1984, 160[:], 386-397[, 1984].
- [00174] 43. McDaniel et al., Microbial Pathogenesis, 1986, 1[:], 519-531[, 1986].
- [00175] 44. McDaniel et al., J. Exp. Med., 1987, 165[:], 381-394[, 1987].
- [00176] 45. Crain et al, [Infect.Immun.] Infect. Immun., 1990, 56[:], 3293-3299[, 1990].
- [00177] 46. B.A. Ralph[, B.A.,] et al., Ann. N.Y. Acad. Sci. 1994[:], 730[:], 361-363.

Substitute Specification Correction Page 44(a)

- [Corresponds to Page 44 of Originally Filed Specification] -

Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])

Appendix A
Version With Markings to Show Changes Made
Page 72 of 72

[00178] 47. E. Alonso DeVelasco[, E.,] et al., Microbiological Rev. 1995[;], 59[:],
591-603.

Substitute Specification Correction Page 44(b)
- [Corresponds to Page 44 of Originally Filed Specification] –
Paragraph Nos. Correspond to Clean Version of Substitute Specification (e.g. [0001])